



**UNIVERSITE DE LIEGE
FACULTE DE MEDECINE VETERINAIRE
DEPARTEMENT CLINIQUE DES EQUIDES
CHIRURGIE DES EQUIDES
FUNDAMENTAL AND APPLIED RESEARCH
FOR ANIMALS AND HEALTH
Promoteur : Pr Didier Serteyn**

**UNIVERSITE DE NAMUR
FACULTE DES SCIENCES
DEPARTEMENT DE BIOLOGIE
UNITE DE RECHERCHE EN BIOLOGIE
CELLULAIRE – NAMUR RESEARCH
INSTITUTE FOR LIFE SCIENCES
Promoteur : Pr Patsy Renard**

COTUTELLE

Equine muscle-derived mesenchymal stem cells as cell therapy for osteoarthritis and influence of priming with a hydrosoluble form of curcumin

Lola Dechêne

**THESE PRESENTEE EN VUE DE L'OBTENTION DU GRADE DE
DOCTEUR EN SCIENCES VETERINAIRES ET EN SCIENCES**

ANNEE ACADEMIQUE 2020-2021



UNIVERSITE DE LIEGE
FACULTE DE MEDECINE VETERINAIRE
DEPARTEMENT CLINIQUE DES EQUIDES
CHIRURGIE DES EQUIDES
FUNDAMENTAL AND APPLIED RESEARCH
FOR ANIMALS AND HEALTH

UNIVERSITE DE NAMUR
FACULTE DES SCIENCES
DEPARTEMENT DE BIOLOGIE
UNITE DE RECHERCHE EN BIOLOGIE
CELLULAIRE – NAMUR RESEARCH
INSTITUTE FOR LIFE SCIENCES

Equine muscle-derived mesenchymal stem cells as cell therapy for osteoarthritis and influence of priming with a hydrosoluble form of curcumin

Lola Dechêne

Composition du jury :

Prof. Didier Serteyn (Promoteur ULiège)
Département clinique des équidés, Chirurgie des équidés, FARAH, ULiège, Liège, Belgique

Dr Florence Chainiaux (Présidente UNamur)
Unité de recherche en Biologie Cellulaire (URBC) Narilis, UNamur, Namur, Belgique

Dr Alexandra Salciccia
Département clinique des équidés, Chirurgie des équidés, FARAH, ULiège, Liège, Belgique

Prof. Patsy Renard (Promoteur UNamur)
Unité de recherche en Biologie Cellulaire (URBC) Narilis, UNamur, Namur, Belgique

Prof. René van Weeren
Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands

Dr Olivier Malaise
Laboratoire de rhumatologie, GIGA, CHU de Liège, ULiège, Liège, Belgique

Prof. Véronique Delcenserie (Présidente ULiège)
Département de sciences des denrées alimentaires, FARAH, ULiège, Liège, Belgique

Prof. Basile Stamatopoulos
Laboratoire de thérapie cellulaire clinique, Institut Jules Bordet, ULB, Bruxelles, Belgique

Dr Fanny Hontoir
Unité de recherche intégrée vétérinaire (URVI), Narilis, UNamur, Namur, Belgique

- Août 2021 -

Remerciements

Ca y est, le temps de l'écriture des remerciements est arrivé. A mes yeux, cela concrétise la fin de 4 magnifiques années et d'une très belle période de ma vie, non sans regrets que cela soit déjà fini... Ma motivation à réaliser une thèse de doctorat a toujours été de recevoir une formation scientifique de qualité pour apprendre et comprendre ce que je ne connaissais alors pas. Les sciences se sont découvertes progressivement durant mes études grâce à quelques enseignants clés, merci à vous : Benoît Muylkens nous a sensibilisé dès notre bac 2 au bien-fondé des vétérinaires dans le domaine de la recherche et Laurent Gillet a concrétisé cela en ouvrant son laboratoire aux étudiants vétérinaires. Cette opportunité fut saisie et a débouché sur un stage en recherche dans le laboratoire d'Alain Vanderplaeschen, sous la supervision de Benjamin Dewals et Françoise Myster. Ces personnes ont su me transmettre l'intérêt de la recherche. La satisfaction de ce stage fut un élément déclencheur qui influença l'orientation du commencement de ma vie professionnelle.

Cette thèse de doctorat débuta grâce à la confiance accordée par mes 2 promoteurs qui me permirent de mener à bien ce projet, je vous en suis très reconnaissante. A Didier Sertheyn et son équipe, merci d'avoir fait naître ce projet ambitieux. Il m'a permis de m'approprier tant de techniques et de réaliser cette thèse. Merci à Ari, Justine, Thierry, Hélène, Ange du CORD ainsi qu'à Alex et Nazaré du pôle équin de la CVU pour vos implications respectives durant ces 4 années. Mon dernier merci « liégeois » revient à Caro, une personne dotée d'une énergie incroyable. Nos conversations « poney », « vétérinaire », HEC et même « mitochondriale » furent des moments savoureux à partager. Merci pour toute ta générosité et ta serviabilité, tu es une amie très précieuse !

Merci à la Région Wallonne pour le financement de ce projet ainsi qu'à tous les partenaires du projet CURSTEM. Parmi ces partenaires et malgré les kilomètres nous séparant, Margaux fut une des composantes de la réussite de cette thèse : notre entente, notre complémentarité et notre soutien mutuel nous ont permis d'arriver au but fixé. Sans toi, rien n'aurait été pareil Margaux alors merci !

Cette thèse n'aurait jamais abouti sans le soutien d'une personne incroyablement dévouée et bienveillante à mon égard. Patsy, je te suis éternellement reconnaissante pour tout ce que tu m'as apporté. Dès le premier jour, tu m'as indiqué que ton seul souhait était que j'aboutisse à cette thèse et nous y voilà ! Durant ce chemin sinueux, tu n'as jamais arrêté de me former et de m'apprendre tant de choses, tant en sciences, qu'en relations humaines, en passant par mon anglais et toutes mes présentations. Je ne compte pas le nombre de fois où mon parcours aurait pu en rester là et où tu as rattrapé la situation en plein vol, proposant une alternative avec ton optimisme légendaire. Ta clairvoyance, ton leadership et ta détermination font de toi le promoteur parfait à mes yeux. Jusqu'aux dernières heures passées sur cette thèse, ton soutien aura été permanent et essentiel pour moi. Je mesure

la grandeur de ton implication à mes côtés durant ces 4 années et il n'y aura pas assez de mercis pour cela.

Marc fut embarqué bien malgré lui dans toutes les expériences utilisant la spectrométrie de masse durant cette thèse. Je ne sais pas si l'on peut imaginer ce que représente le défi de former un vétérinaire en spectrométrie de masse pour faire de la protéomique en utilisant des isotopes stables ? Marc l'a fait ! Ces heures passées à m'expliquer, à réfléchir, à essayer, à rater, à relancer des analyses,... se sont toutes déroulées dans une bonne humeur sans faille, y compris lors des dérangements de Marc durant ses vacances pour avancer dans mes analyses. Merci Marc de m'avoir fait confiance et m'avoir transmis tout cela. L'équipe MaSun est composée d'une sous-équipe de l'URBC très particulière : la team poneys. Catherine et Maude, merci pour toutes vos aides respectives pour les FASPs, lors des nombreuses heures d'observation passées au confocal, en western blot,... A vos côtés, ces heures de travail n'ont jamais été difficiles tant nous aimions parler de poneys et puis de chiens. Maintenant je n'ai qu'un souhait : que cette passion puisse continuer à nous rassembler dans les années futures !

Au sein de l'URBC, j'ai rejoint l'équipe Dyso menée par Patsy mais également par Thierry Arnould. L'implication de Thierry au sein de cette thèse, bien loin de ses sujets de recherches, m'a beaucoup touchée. Merci Thierry d'avoir été présent durant ce parcours, ne perdant jamais une opportunité de me transmettre une information scientifique, de me conseiller et surtout, d'avoir fait partie de mon comité de thèse en assumant parfaitement le rôle.

Cette équipe m'a fourni un second PI de terrain ! Damien, je tiens à te remercier sincèrement pour l'intérêt porté à chacun de nous. Ta volonté de connaître et comprendre nos manipulations mais surtout, tes nombreux conseils m'ont permis d'améliorer bons nombres de mes pratiques scientifiques. Merci Damien et n'arrête jamais de transmettre cela !

Merci également à mon voisin de bureau et mon co-équipier Marino pour tous ces moments passés à rire, philosopher, débattre, projeter, questionner,... Je ne pourrais oublier ces tranches de vie et je suis prête à reprendre un bureau à côté du tien lors de notre prochain job ensemble. Merci Céline et Julie pour avoir fait du 4133 ce bureau génial où l'on a évidemment bien travaillé mais également passé tellement de bonnes heures tous ensemble. Merci pour tout votre soutien durant cette thèse ! Je vous souhaite à tous les 3 beaucoup d'épanouissement dans vos nouvelles vies professionnelles.

Je tiens également à remercier tous les autres travailleurs de l'URBC pour avoir fait de ce laboratoire un lieu où j'ai passé 4 excellentes années : Sébastien pour toutes nos conversations et plan camionnette, Antoine pour ta gestion du labo et ton aide quotidienne durant cette thèse ainsi que mes autres collègues, souvent caractérisés par un attrait particulier lié à la nourriture, ce qui a rendu nos pauses plus

« gustatives » : Camille, Jérémy, Myriam, Aude, Jia-Wei, Victor, Christophe, Sophie,... Merci pour tous ces bons moments passés ensemble.

Au niveau scientifique, cette thèse reprend également les travaux de différentes expériences réalisées dans d'autres laboratoires. Merci à Laurence Lagneaux, Isabelle Hamer, Olivier Peulen et Véronique Mathieu pour m'avoir permis de venir travailler chez vous afin de mener à bien ce projet.

Si la dépression ne m'a pas guetté durant cette thèse, ce n'est pas qu'à cause de mon environnement professionnel ni de mon caractère mais grâce à mes proches au soutien infaillible que je remercie profondément : Nicolas, le pilier de ma vie, celui sur qui je peux sans cesse me reposer pour avancer avec calme et sérénité et qui m'offre la vie dont j'ai toujours rêvé ; mes parents qui ont toujours tout fait pour faciliter ma vie quotidienne et qui rendent les semaines plus douces ; mes grands-parents pour leur profond intérêt à nos réalisations et leurs énergies débordantes nous poussant à toujours voir le changement comme une belle opportunité ; mon frère et ma belle-sœur pour votre bienveillance à mon égard et la confiance accordée auprès de votre petit Jean. Merci à tout mon entourage familial si précieux !

Aussi peu conventionnelle que cela puisse paraître, la thèse fut une période de réalisation qui m'a permis de continuer à voir la vie avancer, même en cas d'échecs scientifiques : je remercie chacun des propriétaires m'ayant placé sa confiance pour m'occuper de vos chevaux. Tous ces moments, à la fois beaux et stressants, m'ont assuré une déconnection totale avec ma thèse.

Merci à ma mère vétérinaire, Martine, pour tout ton soutien, ta confiance, ton matériel, ton aide, nos conversations, nos sorties, tes énervements (rares, il faut bien le reconnaître), ta bonne humeur, nos projets, tes conseils, tes réponses à toutes heures du jour et même parfois de la nuit, tes bons plans, ta gestion de situation de crise et ton imparable « c'est normal, tout va bien » alors que je suis moi-même en train de me décomposer sur place à voir ce qui se passe! Aucun doute sur le fait que notre duo est un succès. Quelle chance j'ai eu de te rencontrer et quel plaisir tous ces moments passés ensemble ! Merci Martinus.

Enfin, mes derniers remerciements vont aux membres qui constituent mon jury de thèse. Je vous remercie pour votre implication durant cette phase de réalisation finale. J'ai apprécié vos remarques et discussions échangées lors de la défense privée. Cela m'a permis d'améliorer mon manuscrit et d'aborder la défense publique avec des nouvelles perspectives. Merci pour tout le temps consacré à ce travail.

Abbreviations

ADAMTs	A Disintegrin And Metalloproteinase with Thrombospondin motifs
AFMPS	Agence Fédérale des Médicaments et des Produits de Santé
BM	Bone marrow
BSA	Bovine serum albumin
CID	Collision-induced dissociation
COMP	Cartilage oligometric matrix protein release
COX	Cyclooxygenase
DMEM	Dulbecco's Modified Eagle Medium
DTT	Dithiothreitol
ECM	Extracellular matrix
ELISA	Enzyme-linked immunosorbent assay
EV	Extracellular vesicles
ER	Endoplasmic reticulum
FASP	Filtered-aided sample preparation
FBS	Fetal Bovine Serum
FCCP	Trifluoromethoxy carbonylcyanide phenylhydrazine
FCR	Flux control ratio
FDR	False Discovery Rate
GAG	Glycosaminoglycan
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase
HA	Hyaluronic acid
HP β CD	Hydroxypropyl-beta-cyclodextrin
IAA	Iodoacetamide
IGFBP	Insulin growth factor binding protein
IL	Interleukin
INF- γ	Interferon gamma
IRAP	Interleukin-1 Receptor Antagonist Protein
mdMSCs	Muscle-derived mesenchymal stem cells
MHC	Major Histocompatibility Complex
MMPs	Matrix metalloproteinases
MS	Mass Spectrometry
MSCs	Mesenchymal Stem Cells
NFKB	Nuclear factor kappa B
NO ₂ ⁻	Nitrite

O/N	Overnight
OA	Osteoarthritis
OCR	Oxygen consumption ratio
PFA	Paraformaldehyde
PASEF	Parallel accumulation serial fragmentation
PB	Peripheral blood
PBS	Phosphate-Buffered Saline
PCM	Pericellular matrix
PGE2	Prostaglandin E2
PRP	Platelet-rich plasma
PTM	Post-translational modifications
PVDF	polyvinylidene fluoride
RAO	Recurrent airway obstruction
RPM	Revolutions per minute
RT	Room temperature
SDS	Sodium dodecyl sulfate
SERPIN	Serine proteinase inhibitors
SILAC	Stable isotope labeling by amino acids in cell culture
SLRP	Small leucine-rich proteoglycans
SUIT	Substrate-uncoupler-inhibitor titration
TCA	Trichloroacetic acid
TFA	Trifluoroacetic acid
TGF	Transforming growth factor
TIMPs	Tissue inhibitors of metalloproteinases
TNF- α	Tumor necrosis factor alpha

<i>Abstract</i>	11
1. <i>Context of this thesis</i>	14
2. <i>Introduction</i>	16
2.1. <i>Mesenchymal stem cells</i>	16
2.1.1. Sources of mesenchymal stem cells	16
2.1.2. Potential effects of MSCs	17
2.2. <i>Cell therapy in equine medicine</i>	18
2.3. <i>Osteoarthritis</i>	19
2.3.1. Joint description	20
2.3.2. Osteoarthritis pathology	22
2.3.3. Chondrocyte phenotype during OA pathogenesis	24
2.3.4. Diagnosis	24
2.3.5. Treatment	25
2.3.6. Equine osteoarthritis	25
2.4. <i>Mesenchymal stem cells for osteoarthritis treatment</i>	26
2.4.1. Migration of mesenchymal stem cells	27
2.4.2. Immunomodulation by mesenchymal stem cells	27
2.4.3. Chondroprotective effects of MSCs	28
2.5. <i>Conclusions</i>	29
3. <i>Which model to assess the regenerative potential of cell therapy for osteoarthritis disease?</i>	31
3.1. <i>Introduction</i>	31
3.2. <i>In vitro models of osteoarthritis</i>	31
3.2.1. Chondrocytes	31
3.2.2. Explants	32
3.2.3. Microphysiological systems	33
3.2.4. Inflammatory part of osteoarthritis model	33
3.3. <i>Horse as a model specie for osteoarthritis</i>	35
3.4. <i>Material & Methods</i>	36
3.4.1. Differentiation of mdMSCs to chondrocytes	36
3.4.2. Mass spectrometry analysis	37
3.4.3. Primary chondrocytes	38
3.4.4. Cartilage sample collection	38
3.4.5. Nuclear translocation of NF-kB (P65 immunofluorescence)	38
3.4.6. Nuclear translocation of NF-kB (Western blot analysis of nuclear fractions)	39
3.4.7. RT-qPCR	39
3.4.8. Phenotypic analysis of cartilage plugs: response to inflammatory cytokines	40
3.5. <i>Results: selection of the cellular component of the OA in vitro model</i>	40
3.5.1. Differentiation of mdMSCs in chondrocyte-like cells	41
3.5.2. Culture of chondrocytes	43
3.5.3. Plugs of cartilage	44
3.6. <i>Results: selection of the inflammatory component of the OA in vitro model</i>	45
3.7. <i>Discussion</i>	47
3.8. <i>Conclusions</i>	48
4. <i>Secretome</i>	50
4.1. <i>Introduction</i>	50
4.1.1. MSCs secretome	50
4.1.2. Plasticity	50

4.2.	<i>Horses MSCs secretome</i>	51
4.3.	<i>Secretome analyses</i>	54
4.3.1.	Stable isotope labeling by amino acids in cell culture	55
4.4.	<i>Goals of this part</i>	56
4.5.	<i>Material & methods</i>	56
4.5.1.	LDH assay	56
4.5.2.	Supernatant analysis in serum-free medium	57
4.5.3.	Supernatant analysis in DMEM F12	57
4.5.4.	<i>In vitro</i> osteoarthritis model	57
4.5.5.	Cell culture for SILAC experiment.....	57
4.5.6.	Cartilage sample collection	58
4.5.7.	Secretome analysis by SILAC proteomic analysis	58
4.5.8.	Mass spectrometry analysis - SILAC.....	59
4.5.9.	Cartilage's GAG release.....	60
4.5.10.	Clusterin, decorin & MMP3 abundance (Western blot analysis).....	61
4.5.11.	MMP3 activity fluorometric assay	62
4.6.	<i>Results</i>	62
4.6.1.	Cytotoxicity assay	62
4.6.2.	Secretome analysis of mdMSCs cultured in the serum-free media "StemPro MSC SFM"	62
4.6.3.	DMEM F12 without serum supplementation.....	65
4.6.4.	Secreted proteins identified with stable isotope labeling by amino acids in cell culture.....	68
4.6.5.	Protection of mdMSCs toward cartilage's GAG release	73
4.7.	<i>Discussion</i>	77
4.8.	<i>Conclusions</i>	80
5.	<i>mdMSCs as a drug delivery device</i>	82
5.1.	<i>Introduction</i>	82
5.2.	<i>mdMSCs as drug carrier for NDS27</i>	85
5.3.	<i>Goals of this part</i>	102
5.4.	<i>Material & methods</i>	102
5.4.1.	Mitochondrial respiratory capacity	102
5.4.2.	Flux analyzer	103
5.4.3.	RT-qPCR: Pro-inflammatory gene expression	104
5.4.4.	Cell Suspension.....	104
5.5.	<i>Results</i>	104
5.5.1.	Effects of pro-inflammatory media on mdMSCs mitochondria.....	104
5.5.2.	Influence of NDS27 priming on adherent mdMSCs in pro-inflammatory media.....	105
5.5.3.	Cell suspension.....	106
5.6.	<i>Discussion</i>	108
5.7.	<i>Conclusions</i>	109
6.	<i>Conclusions & perspectives</i>	111
7.	<i>Supplementary files</i>	116
7.1.	<i>SILAC ratio</i>	116
7.2.	<i>Donors' informations</i>	118
8.	<i>Bibliography</i>	120

Abstract

Abstract

Osteoarthritis is a high prevalent joint degenerative disease for which therapeutic treatments are limited or invasive. Cellular therapy based on mesenchymal stem cells is therefore seen as a promising approach for this disease. This research project works with equine mesenchymal stem cells harvested in muscle, an easy access site, with a minimally invasive process.

As curcumin is described to improve the osteoarthritis pathology by decreasing the pain and the stiffness of the joint, the goal of this project was to study the combination of both muscle-derived mesenchymal stem cells (mdMSCs) and a hydrosoluble form of curcumin called NDS27.

We have first developed an *in vitro* model of osteoarthritis disease in order to evaluate the potential clinical effect of this innovative product. This model is focus on cartilage (*ex vivo* explant) and its response in pro-inflammatory (TNF- α and IL-1 β) culture conditions.

Then, as regenerative potential of MSCs is mainly conferred by paracrine function, we have characterized the secretome of mdMSCs in this *in vitro* model of OA (explant of cartilage with TNF- α and IL-1 β). Mass spectrometry analyses identified several actors secreted by mdMSCs. According to the dual function of these secreted proteins, implicated both in catabolic and anabolic cartilage functions, we performed functional tests consisting of studying the effect of mdMSCs cultured with explants of cartilage in pro-inflammatory model. Results showed that mdMSCs decreased the glycosaminoglycan release from plugs of cartilage in this model, supporting the anti-catabolic effect of mdMSCs in these conditions, potentially explained by the increase of secreted decorin and the decreased abundance and activity of MMP3.

Finally, we have demonstrated that NDS27 is able to penetrate into mdMSCs and localizes into mitochondria, at least partially. Optimizations between conditions leading to maximal incorporation of NDS27, regenerative properties and constraints of industrial partner (to fit with good manufacturing practice) must now be done.

Résumé

L'arthrose est une maladie dégénérative articulaire touchant un grand nombre de personnes et pour laquelle, peu d'options thérapeutiques existent, hormis les traitements traditionnels ou invasifs. Les thérapies cellulaires à base de cellules souches mésenchymateuses sont vues comme des traitements prometteurs en raison de leurs capacités régénératrices. Ce travail de recherche a étudié des cellules souches mésenchymateuses récoltées dans les muscles de chevaux par une technique peu invasive et facile à réaliser.

La curcumine est un polyphénol largement décrit pour ses effets bénéfiques sur les articulations arthrosiques en réduisant notamment la douleur et la raideur provoquées par cette maladie. L'objectif de ce travail est d'étudier le potentiel thérapeutique de cellules souches mésenchymateuses d'origine musculaire (mdMSCs) traitées avec une molécule de curcumine soluble appelée NDS27.

Nous avons tout d'abord développé un modèle *in vitro* d'arthrose afin d'étudier le potentiel thérapeutique du produit étudié. Ce modèle consiste à placer en culture un prélèvement *ex-vivo* de cartilage avec un milieu pro-inflammatoire constitué de TNF- α and IL-1 β .

Ensuite, comme les propriétés régénératives des cellules souches mésenchymateuses sont majoritairement attribuées à la fonction paracrine de ces cellules, nous avons caractérisé le sécrétome des mdMSCs dans ce modèle *in vitro* d'arthrose (constitué d'un explant de cartilage et des cytokines pro-inflammatoires TNF- α and IL-1 β). Les analyses par spectrométrie de masse nous ont permis d'identifier des protéines sécrétées par les mdMSCs dans ces conditions. L'ensemble de ces protéines étant décrites pour exercer des fonctions anaboliques et cataboliques, nous avons réalisé un test fonctionnel pour évaluer l'effet des mdMSCs dans ce modèle. Nous avons pu montrer l'effet anti-catabolique des mdMSCs : la libération de glycosaminoglycans des explants de cartilage en milieu pro-inflammatoire était diminuée lorsque ces explants étaient cultivés en présence de mdMSCs. Cet effet est partiellement expliqué par l'augmentation de la sécrétion de la decorin et la diminution de l'abondance ainsi que l'activité de l'enzyme MMP3.

Enfin, nous avons démontré que le NDS27 était internalisé dans les mdMSCs et partiellement localisé au niveau des mitochondries. Le potentiel thérapeutique de ce produit devra encore être démontré après optimisation des conditions de préparation du produit permettant une incorporation maximale du NDS27, favorisant les propriétés régénératives du produit et respectant les contraintes de fabrication auxquelles doit répondre le partenaire industriel.

Context of this thesis

1. Context of this thesis

This thesis is part of the Curstem project which was supported by the grant WALInnov program from the Wallonie recherche SPW, convention number 1610151. This project involves several partners including another PhD program (Margaux Colin, ULB) whose research is complementary to the results presented in this manuscript. The goal of this project was to develop an innovative cell therapy product for horse osteoarthritis (OA) disease including muscle-derived mesenchymal stem cells (mdMSCs) treated with a hydrosoluble form of curcumin called NDS27.

This work includes first an introduction on mesenchymal stem cells (MSCs) and OA based on literature. Then, results are presented in 3 parts. Each part includes a brief review of literature, the material and methods, the results, the discussion and conclusions. These parts are:

- Development of the *in vitro* OA model used
- Characterization of the mdMSCs secretome
- Potential of mdMSCs use as drug-carrier for NDS27 in the context of OA disease

Finally, a general conclusion will close this research work.

Introduction

2. Introduction

2.1. Mesenchymal stem cells

Mesenchymal stem cells (MSCs) are non-hematopoietic multipotent stem cells which were first described in 1970 (Friedenstein, Chailakhjan, & Lalykina, 1970). Physiological functions of these adult stem cells are maintenance of body homeostasis and tissue repair (Vizoso et al., 2017). In 2006, the International Society for Cellular Therapy defined minimal criteria to characterize human MSCs: plastic-adherent in cell culture, expression of CD105, CD90, CD73 and lack expression of CD45, CD34, CD19, CD14 and HLA-DR surface molecules. In addition, a last criteria concerned the MSC's *in vitro* differentiation potential to osteoblasts, adipocytes and chondroblasts (Dominici et al., 2006).

MSCs have been of increasing interest over the last years because they display several key properties for cell therapy, either for regenerative medicine or in immune diseases (N. Li & Hua, 2017). Indeed, MSCs are easy to isolate, display a large differentiation potential, and have a strong self-renewal capacity, a key feature to obtain the large number of cells required for cell therapy (Naji et al., 2019). In addition, MSCs expression of major histocompatibility complex (MHC) is low, which explains minor immunological rejection of the organism towards these cells (Harrell, Markovic, et al., 2019). Moreover, migratory and homing abilities into regions of injury are two described properties of MSCs which confer MSCs an interesting therapeutic potential (Driscoll & Patel, 2019). This rely partly on the release of proteolytic enzymes by MSCs that explains their capacity for diapedesis across the endothelium (De Becker & Van Riet, 2016). Finally, the absence of ethical controversy about MSCs contributes to their widespread use (Mocchi et al., 2020).

2.1.1.Sources of mesenchymal stem cells

The main tissue sources of MSCs are primarily the umbilical cord for neonatal tissue and bone marrow (BM) or adipose tissue for adult tissues (Hass, Kasper, Böhm, & Jacobs, 2011). However, these cells can be harvested from many other vascularized tissues like peripheral blood (PB), lung, synovial fluids, periodontal ligaments or muscles (Samsonraj et al., 2017). Skeletal muscle has the advantage to represent approximately 35% of human body mass and to be easily accessible (Ceusters et al., 2017). MSCs source is important to consider because differentiation potentials and biological features may vary depending on sampled tissue (Sacchetti et al., 2016). Neonatal tissues are of utmost interest as the MSCs yield decreases as the age of the donor increases (Kern, Eichler, Stoeve, Klüter, & Bieback, 2006).

Skeletal muscle hosts different populations of stem cells that maintain tissue homeostasis (Judson, Zhang, & Rossi, 2013). The high healing capacity of muscle suggests that it is a tissue composed of cells able to participate in tissue regeneration. mdMSCs are able to differentiate into osteoblasts,

adipocytes and chondrocytes *in vitro* and exhibit the same trophic properties than MSCs harvested from BM (Jackson et al., 2010). mdMSCs' regeneration can be altered in disease and lead to muscle fibrosis, fatty tissue accumulation and deposition of extracellular matrix (ECM) proteins (Judson et al., 2013). Satellite cells, and quiescent myoblast precursors are also muscle-specific stem cells but their differentiation potential is limited (they differentiate only in myogenic cells) compared to mdMSCs (Jackson et al., 2010). mdMSCs is described to be an attractive source for medical therapy according its relative ease of isolation and purification (Usas & Huard, 2007). A minimally invasive process based on muscular micro biopsy allowing to harvest a high yield of MSCs has been developed in horses and meets the above mentioned criteria (Ceusters et al., 2017).

2.1.2. Potential effects of MSCs

Whether the therapeutic effects of MSCs is mainly due to their differentiation properties or to their paracrine properties was a matter of debate for years. Nowadays, it is largely admitted that the principal therapeutic mechanism of mesenchymal stem cells is the paracrine function and not the engrafting and differentiating properties because the survival of cells is short (Vizoso et al., 2017). Moreover, the number of differentiated cells identified after injection is too small to explain a therapeutic effect (Ferreira et al., 2018).

However, the extent of the immunomodulatory effect of MSCs depends on several parameters. First, the immunomodulatory properties of MSCs are dependent on the inflammatory level in the microenvironment (N. Li & Hua, 2017). Pro-inflammatory stimuli lead especially the secretion of immunosuppressive molecules like TGF- β (Kim & Cho, 2016), which is also an actor inducing MSCs homing (H. Liu, Li, Zhang, & Li, 2018). These stimuli enhance the secretion of anti-inflammatory proteins (such as heme oxygenase) which could favor the anti-inflammatory phenotype of macrophages (M2) (Kim & Cho, 2016; Ragni et al., 2020). Therefore, priming MSCs with cytokines could be a strategy used to increase their trophic factor for therapies (Redondo-Castro et al., 2017).

Second, the routes for administration are important to consider because this step influences cell activity and survival in particular depending on needle types, aspiration and re-injection of cells. Routes are selected depending on pathologies and risks: thrombosis is the major risk of intra-arterial route injections (Sole et al., 2012).

In addition, it has to be mentioned that for clinical application, expansions beyond four passages lead to senescence with a decrease of proliferation accompanied with morphological and biological changes (Mocchi et al., 2020).

Questions about working with autologous or allogeneic cells always arise. Although using autologous cells for therapy might appear as the most appropriate material according to immunocompatibility, supply and ethics considerations, several drawbacks do exist. First, harvesting cells of a sick donor could

result in a reduction of clonogenic cells, proliferative rate, differentiation and angiogenic potential (Rozier et al., 2018). Moreover, approximately 3 weeks are necessary to obtain sufficient cell quantities from harvesting to implantation, therefore treating a patient in acute phase with autologous cells might not be possible (Zayed et al., 2018). On the other hand, exposing the patient to multiple allogeneic MSCs could be deleterious for diseases like OA because of the activation of adaptive immune response (Joswig et al., 2017). Indeed, allogeneic MSCs can express MHC II after engraftment and lose their immune privileged status (Huang et al., 2010).

Despite high immunomodulatory properties, side effects of cell therapy were also described. For instance, paracrine factors secreted by MSCs can interact with tumor cells, especially by increasing angiogenesis, which favors metastasis (Samsonraj et al., 2017). Aberrant differentiation is also a reported limitation for using MSCs (Driscoll & Patel, 2019). Therefore, a balance between benefit and risk of MSCs therapy must be measured.

2.2. Cell therapy in equine medicine

Cell therapy has several described applications especially for orthopedic conditions in horses (Voga, Adamic, Vengust, & Majdic, 2020). In addition to the well-known musculoskeletal applications, these cells are also used in equine ophthalmology, reproduction, metabolic disorders, respiratory systems, integumentary system, neurological disorders and endotoxemia (Cequier, Sanz, Rodellar, & Barrachina, 2021).

Several sources of MSCs have been described in the horse and are similar to humans: BM, adipose tissue, synovium, umbilical cord, tendon, muscle, gingiva or periodontal ligament (Ortved & Nixon, 2016). Harvesting BM-MSCs represents several complication risks: infection, hemorrhage and especially pneumothorax or pneumopericardium in the horse (Vidal et al., 2007). Adipose tissue offers an easier and safe access with rapid recovery after harvest. Umbilical cord blood is a readily available and highly proliferative source of horse MSCs but caution must be applied about the non-sterile conditions during parturition (Passeri et al., 2009).

Although several studies have been conducted with MSCs for horses, it is difficult to draw a coherent picture since they report highly variable results whatever the disease considered, depending on the source of MSCs, cell isolation procedure, culture condition or the administration routes (reviewed in (MacDonald & Barrett, 2020)).

Currently there is no central legislation for veterinary cell therapy in Europe (Voga et al., 2020). In Belgium, the use of stem cell therapy is regulated by the Agence Fédérale des Médicaments et des

Produits de Santé (AFMPS) and veterinary use is subject to the law related to drugs of 25 March 1964 (AFMPS, 2018): medicinal product need to obtain the AFMPS' approvement before marketing.

2.3. Osteoarthritis

Osteoarthritis (OA) is a degenerative disease that concerns over 10% of people over 60 years of age worldwide and etiology is multiple and includes genetics, metabolic factors, inflammation and trauma (Arrigoni et al., 2020). Knee and hip, two large weight-bearing joints, are the most commonly affected (He et al., 2020). The joint is a complex organ formed by several tissues (figure 1A). The proper function of this organ is conditioned by a finely tuned balance between anabolic and catabolic processes of these several joint constituents (Piluso et al., 2019).




Figure 1 : A) Joint is composed of bone, cartilage, synovial membrane and liquid (Hunter & Bierma-Zeinstra, 2019). B & C) Molecular composition (B) and structure (C) of hyaline cartilage (Pawlina, 2019).

2.3.1. Joint description

- The **articular cartilage** is hyaline cartilage (figure 1B). It has different functions which depend on the developmental stage: cartilage is the template for long bone formation during growth and acts as shock-absorber for adult bone (Cohen, Foster, & Mow, 1998). The cartilage allows to

absorb and translate the force supported by the joint during movements thanks to its rich and very specific ECM (Thysen, Luyten, & Lories, 2015). Cells of this smooth and gliding surface are mostly chondrocytes but articular cartilage-derived progenitor cells have also been identified in cartilage (Alsalameh, Amin, Gemba, & Lotz, 2004). This population of progenitor cells represents up to 1% of cartilage cell content (Levato et al., 2017). Chondrocytes synthesize a very specific and abundant ECM (Charlier et al., 2019). The role of cartilage ECM is to confer tensile and compressive strengths properties (Poole et al., 2001). Chondrocytes are responsible for the synthesis and maintenance of the ECM (Zayed et al., 2018).

- The ECM production requires a high protein synthesis as evidenced by the large and highly developed Golgi apparatus and endoplasmic reticulum of chondrocytes (Armiento, Alini, & Stoddart, 2019). Chondrocytes produce mainly three types of collagen: II (90%), IX (1%) and XI (3%) (Eyre, 2002). In addition to these collagens, ECM is also composed of other proteins (figure 1C):
 - Proteoglycans: The shock-absorber function is conferred by the large volume of water bound to proteoglycans that are proteins modified with negatively charged glycosaminoglycans (GAG) (Armiento et al., 2019). Aggrecan is the major proteoglycan in cartilage (Q. Li et al., 2020). The core of this protein is linked to over 100 GAG molecules (Krishnan & Grodzinsky, 2018). In the cartilage ECM, proteoglycans such as aggrecan have the particularity to bind long hyaluronan molecules, by link proteins, to form large proteoglycan aggregates. These highly charged proteoglycan aggregates are bound to the collagen matrix fibrils that are associated with collagen network (Han et al., 2019). Versican and small leucine-rich proteoglycans (SLRP) such as decorin or lumican are other proteoglycans found in cartilage (Krishnan & Grodzinsky, 2018).
 - Fibers: In addition to the most prominent collagen type II, and to less abundant collagen types IX and XI, the ECM also contains collagen types III, V, VIII, X, XII, XIII, XIV and elastin (Gao et al., 2014).
 - Multi adhesive glycoproteins: Fibronectin and laminin are also identified in the ECM of cartilage (Gao et al., 2014). Other glycoproteins play different roles in the articular cartilage like clusterin, a glycoprotein implicated in immune response (Chen, Fu, Wu, & Pei, 2017).
- Several enzymes are implicated in the maintenance of ECM and can be classified according to their substrates: collagenases are matrix metalloproteinases (MMPs) 1, 8 and 13 (table 1); aggrecanases are a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTs) 4 and 5. Plasmin, a serine proteinase, is the active form of the pro-enzyme plasminogen and has several actions in cartilage: to cleave

fibronectin, proteoglycans or to activate proMMPs. Endogenous inhibitors of these proteinases are respectively tissue inhibitors of metalloproteinases (TIMPs) and Serine proteinase inhibitors (serpins) (Wilkinson, Arques, Huesa, & Rowan, 2019).

The narrow tissue surrounding the chondrocyte is called pericellular matrix (PCM) and forms the “chondron” together with the cells. PCM distinguishes from ECM by the presence of collagen type VI (Gao et al., 2014).

Cartilage is not vascularized and this particular environment has critical consequences on cell populations. First, chondrocytes have adapted their metabolism to anaerobic conditions (Buckwalter, 2002) and the articular cartilage is not able to self-renew (Jiang et al., 2016). Chondrocytes present a plasticity that allows them to modify their phenotype during disease and to become hypertrophic during OA for example (Charlier et al., 2019).

- The **subchondral bone** is protected by articular cartilage from forces on the joint surface (Ortved & Nixon, 2016).
- Joints are notably delimited by a **synovial membrane** (or synovium), composed by synoviocytes that produce the synovial fluid resulting from a mixture between plasma dialysate and hyaluronic acid (HA). The microstructure of this membrane is unique because fenestrations and pores allow the membrane to act as a sieve (Goodrich & Nixon, 2006). Cells form a single layer and a loose connective tissue with blood vessels and nerves to constitute the synovial membrane (Pujol et al., 2018). This membrane is supported by a outer fibrous layer which is the capsular ligament (Goodrich & Nixon, 2006).
- The **synovial fluid** has a function of cartilage nourishment by diffusion because cartilage is not vascularized. Another function of this fluid is to lubricate the articular surface (Zayed et al., 2018).

2.3.2. Osteoarthritis pathology

OA is a chronic condition that leads to irreversible tissue degradation due to inflammation (Zeira et al., 2018). Lesions are multiple and concern all constituents of the joint environment: cartilage degradation, synovial inflammation and bone lesions (osteophytes, subchondral sclerosis and BM lesions) (Lee et al., 2020) (figure 2). Synovial cells, immune cells, osteoblasts, chondrocytes or adipocytes are cells present in the joint and able to release inflammatory mediators contributing to the initiation and perpetuation of OA pathogenesis (Berenbaum, 2013). The early inflammatory response is influenced by the innate immune cells while cells of adaptive immunity lead to the chronic phase of the disease (Harrell, Markovic, et al., 2019). If components of cartilage’s decomposition are exposed to B cells,

autoantibodies are produced and deposited in articular cartilage, making an immune complex that activates the complement system and induces tissue damage (Möding et al., 2019).

Pro-inflammatory cytokines activate inflammatory cells and promote the expression of hydrolytic enzymes such as MMPs (table 1), ADAMTs or cathepsin K (Bertuglia, Pagliara, Grego, Ricci, & Brkljaca-Bottegaro, 2016).




Figure 2: Consequences of OA on joint constituents and their molecular actors implicated in this pathology (Hunter & Bierma-Zeinstra, 2019).

Enzyme	Pseudonyms	Collagen Substrates	Additional Substrates
MMP-1	Collagenase-1	I, II, III, VII, VIII, X	Aggrecan, Gelatin
MMP-2	Gelatinase A	I, II, III, IV, V, VII, X, XI	Aggrecan, Elastin, Fibronectin, Gelatin, Laminin
MMP-3	Stromelysin-1	II, III, IV, IX, X, XI	Aggrecan, Elastin, Fibronectin, Gelatin, Laminin
MMP-4	Identified as MMP-3	-	-
MMP-5	Identified as MMP-2	-	-
MMP-6	Identified as MMP-3	-	-
MMP-7	Matrilysin	IV, X	Aggrecan, Elastin, Fibronectin, Gelatin, Laminin
MMP-8	Collagenase-2	I, II, III, V, VII, VIII, X	Aggrecan, Elastin, Fibronectin, Gelatin, Laminin
MMP-9	Gelatinase B	IV, V, VII, X, XIV	Aggrecan, Elastin, Fibronectin, Gelatin
MMP-10	Stromelysin-2	III, IV, V	Aggrecan, Elastin, Fibronectin, Gelatin, Laminin
MMP-11	Stromelysin-3	Aggrecan, Fibronectin, Laminin	-
MMP-12	Macrophage	IV	Elastin, Fibronectin, Gelatin, Laminin
MMP-13	Collagenase-3	I, II, III, IV	Aggrecan, Gelatin

MMP-14	MT1-MMP	I, II, III	Aggrecan, Elastin, Fibronectin, Gelatin, Laminin
MMP-15	MT2-MMP	Fibronectin, Gelatin, Laminin	-
MMP-16	MT3-MMP	-	-
MMP-17	MT4-MMP	Fibrin, Gelatin	-
MMP-18	Identified as MMP-19	-	-
MMP-19	RASI-1	IV	Aggrecan, Fibronectin, Gelatin, Laminin, COMP
MMP-20	Enamelysin	Aggrecan, Amelogenin, COMP	-
MMP-21	X-MMP	-	-
MMP-22	C-MMP	-	-
MMP-23	-	-	-
MMP-24	MT5-MMP	-	-
MMP-25	MT6-MMP	IV	Fibronectin, Gelatin, Laminin
MMP-26	Matrilysin-2	IV	Fibronectin, Gelatin
MMP-27	-	-	-
MMP-28	Epilysin	-	-

Table 1: Matrix metalloproteinase family contains several members with different substrates. MT: membrane type (Araki & Mimura, 2017).

2.3.3. Chondrocyte phenotype during OA pathogenesis

As mentioned before, chondrocytes participate in the OA pathogenesis, especially by a modified secretory phenotype. Matrix proteins, matrix proteases and matrix protease inhibitors, inhibin/activin or clusterin are differentially expressed molecules in the secretome of OA chondrocytes (Trachana, Mourmoura, Papathanasiou, & Tsezou, 2019). Matrix proteases, as MMP (summarized in the table 1), degrade the ECM by using different cartilaginous substrates. This modification of microenvironment leads chondrocyte to form clusters (Pearle, Warren, & Rodeo, 2005). This cell arrangement modifies the ECM secreted by chondrocytes, such as the decrease of proteoglycans production (Maldonado & Nam, 2013). This field is therefore a promising approach to identify new biomarkers linked to OA disease (Sanchez et al., 2017).

Another chondrocyte modification during the disease concerns mitochondria that present several dysfunctions participating in the pathogenesis. ROS increase is observed and explained by several mechanisms: decrease of the anti-oxidant molecules like superoxide dismutase 2, impairment of mitochondrial integrity and so in electron transport chain (Loeser, Collins, & Diekman, 2016). These dysfunctions participate in the increased chondrocyte catabolism.

2.3.4. Diagnosis

OA diagnosis is performed on clinical symptoms and radiographic findings (Liao et al., 2018), similarly in man and horse. The primary symptom of OA is pain (Pujol et al., 2018). Articular surfaces are not only non-vascularized structures, they are also aneural tissues, which explains the low perception of pain when there is articular damage. On the contrary, synovial membrane, subchondral bone and periosteum are innervated structures that perceive and transfer pain signals (van Weeren & Back, 2016). Therefore, detection of early stages of OA is particularly challenging because early OA can be asymptomatic and due to the lack of sensitivity for minimal cartilage lesions on x-rays (Liao et al., 2018). X-rays-based diagnostic is limited to the detection of advanced lesions. Indeed, bone mineral

density must change at least by 30-40% to observe a modification on X-rays (C. Wayne McIlwraith et al., 2018).

The development of OA is slow, unpredictable and a shift exists between clinical signs and molecular events (McCoy, 2015). Proteomic research is currently seen as interesting field to identify candidate biomarkers, to highlight molecular mechanisms involved and to facilitate early OA diagnosis (Liao et al., 2018). The most promising indicator of MMPs activity is the biomarker from type II collagen degradation used both in human and animal models (Charni, Juillet, & Garnero, 2005).

2.3.5. Treatment

Principal therapies are symptomatic with administration of anti-inflammatory drugs. Surgery (joint replacement) is the only option available for joints with high grade of OA. The main challenge is to identify therapeutic strategies decreasing the progression of the disease and treating existing lesions (Thysen et al., 2015). Therefore, regenerative therapies based on stem cells are promising treatments for joints suffering from OA and several clinical trials showed that stem cell therapy can be a reliable treatment for this disease (Arrigoni et al., 2020).

2.3.6. Equine osteoarthritis

Major causes of retirement for sport horses are joint diseases and OA (Ortved & Nixon, 2016). Carpus and metacarpophalangeal joints are the most common affected joints of racehorse while the stifle is the most affected joint with OA for Western performance horses (C. W. McIlwraith, Frisbie, & Kawcak, 2012). OA concerns more than 50% of horses older than 15 (van Weeren & Back, 2016) and 60% of lameness is related to OA (Bertoni et al., 2020). Microtrauma, synovitis or a major joint trauma are probably the most frequent etiologies for equine OA. Lameness caused by OA presents an intermittent character with switches between symptomatic at asymptomatic phases (van Weeren & Back, 2016).

Curative treatment does not exist up to now in equine medicine, so management of the horse and traditional therapies are the main ways to act on the disease. Joint arthrodesis can be performed for horses suffering from end stage OA (Ortved & Nixon, 2016). Management principles include maintaining adequate body weight, assuring good housing conditions with soft surfaces, consider specific shoeing, balance joint stability with controlled exercise and treat every flare-up of OA (van Weeren & Back, 2016). Anti-inflammatory molecules used are mostly steroids for intra-articular way and non-steroid molecules for systemic delivery in horses. These treatments are cost effective and could quickly relief pain. Hyaluronic acid is used in equine medicine to increase the synovial liquid viscosity, to improve shock absorption and then to decrease inflammation (Azambuja da Silva, Pinto da Rosa, Mackmill, & Roll, 2021). Hydrogel is also used for synovial fluid substitute: this safe and lasting product reduces the lameness in horses suffering from OA (Tnibar et al., 2015).

Strategies leading to cartilage repair include several biological therapies. Autologous conditioned serum (also called Interleukin-1 Receptor Antagonist Protein (IRAP)) is obtained from PB and after different steps to concentrate endogenous molecules like IL-1 receptor antagonist (Linardi, Dodson, Moss, King, & Ortved, 2019). Platelet-rich plasma (PRP) is also described to contain regenerative factors from platelets like TGF- β 1 (Textor, Willits, & Tablin, 2013). Cell therapy in equine medicine is growing in interest with chondrocyte implantation, MSCs administration or bioengineered cartilage (Ortved & Nixon, 2016). Variable results are reported in treating naturally occurring OA in horse with MSCs because this disease is heterogeneous in terms of duration and severity (Mocchi et al., 2020). IRAP, PRP and stem cells are reported to be used at respectively 83,3%, 72,5% and 53,7% in a recent US study about joint therapy in equine practice (Zanotto & Frisbie, 2021).

2.4. Mesenchymal stem cells for osteoarthritis treatment

Treating OA with intra-articular injection of MSCs has been described to decrease joint inflammation and lead to cartilage regeneration in several animal species (such as mice, rats, pigs, horses or donkeys) (Harrell, Markovic, et al., 2019). Clinical studies have already been performed in human medicine with improvement of clinical outcomes (Jang, Lee, & Ju, 2021). Mechanisms of action of these cell therapies in the OA context are described below and are summarized in the figure 3.




Figure 3: OA therapy based on MSCs helps to maintain articular tissue homeostasis by improving the cartilage regeneration and decreasing the inflammatory environment of the joint. Several MSCs secreted factors are involved to achieve these functions (R. Zhang, Ma, Han, Zhang, & Ma, 2019).

Therapeutic properties result from the capacity of MSCs to join the injury, to secrete trophic factors to allow regeneration and to modulate the inflammatory environment of OA. OA therapy should allow cartilage regeneration but also modulate immune cells activities according to their major impact in the pathology of this disease (X. Zhao et al., 2020).

2.4.1. Migration of mesenchymal stem cells

To reach the lesion sites, MSCs need to have efficient homing properties to migrate at the site of injury and exert their immunomodulatory properties (Nitzsche et al., 2017). First, migration is regulated by the presence of chemokines and their binding to MSCs chemokine receptors. Then, MSCs use their adhesion molecules like integrins to interact with cells. Finally, MMP in the extracellular matrix or secreted allow migration toward tissues (Naji et al., 2019).

2.4.2. Immunomodulation by mesenchymal stem cells

OA is not only a mechanical joint injury: inflammatory and immune systems are also implicated in this pathology. Macrophages, T and B cells are the main cells involved in OA immune response (X. Zhao et al., 2020). MSCs are able to interact with immune cells implicated in OA by cell-to-cell contacts (juxtacrine) or through the production of soluble factors (paracrine way) (Harrell, Markovic, et al., 2019) (figure 4).




Figure 4: Pro-inflammatory cytokines like interferon gamma or TNF- α lead to the secretion of bioactive factors by MSCs and explain the modulation of MSCs toward immune cells by different mechanisms: regulation of macrophages polarization, inhibition of T cells proliferation, induction of immunosuppressive Treg and decreased B-cell activation. (X. Zhao et al., 2020)

These secreted factors constitute the secretome and are soluble proteins, nucleic acids, lipids or extracellular vesicles (EV) (Harrell, Fellabaum, et al., 2019).

- **Soluble factors:** The secretome of MSCs contains a plethora of soluble factors like ECM actors, cytokines, proteases or protease inhibitors (Mancuso, Raman, Glynn, Barry, & Murphy, 2019). Among others, anti-inflammatory factors (like IL-10) or anti-catabolic factors (like TIMPs) are secreted by MSCs in OA context (Richardson et al., 2016).
- **EV** are described to induce similar immunomodulatory and anti-inflammatory effects than parental cells. Therefore, their properties are already studied in several disease models. EV are surrounded by a lipid bilayer and are naturally secreted by cells to allow intercellular communication (Qiu et al., 2019). Size and origin of EV differ and are therefore classified as apoptotic bodies (>1000nm, formed during apoptosis), microvesicles (100-1000nm, of plasma membrane origin) or exosomes (30-200nm, formed during endosomal process) (Harrell, Fellabaum, et al., 2019). EV contain proteins, RNA and/or DNA and can induce signaling of recipient cells by endocytosis, fusion or binding to specific receptors. As non-cellular therapy, MSC-EVs present a low immunogenicity and good *in vivo* stability (Lai, Weng, Guo, Chen, & Du, 2019). However, EV-based therapy has several disadvantages reviewed in X. Zhao and al.: i) They are not able to reproduce the contact effect of MSCs; ii) EVs undergo a rapid clearance so local delivery is important ; iii) EV present variable effects due to several factors related to MSCs sources, isolation, culture, cryopreservation, ... (X. Zhao et al., 2020)

In OA context, chondrocytes can incorporate EVs from MSCs, leading to downregulate pro-inflammatory actors (like IL-6, IL-8, COX-2) and the release of proteases (Alcaraz, Compañ, & Guillén, 2019).

- **Fragmented, metabolically inactivated or apoptotic MSCs** also possess an immunomodulation potential (A. R. R. Weiss & Dahlke, 2019). By indirect effect, apoptotic cells decrease the reactivity of immune cells: apoptotic cells are phagocyted by macrophages which induces expansion of Treg cells and fail to induce CD4 T helper cells (Griffith et al., 2007). Moreover, dead or fragmented cells should have less tumor induction capacity than living MSCs (A. R. R. Weiss & Dahlke, 2019).

2.4.3. Chondroprotective effects of MSCs

Anti-inflammatory and chondroprotective effects of MSCs on chondrocytes are due to the decreased production of inflammatory mediators (TNF- α , IL-1 β , IL-6, nitric oxide) and the enhanced production

of immunosuppressive molecules like IL-10 (Harting et al., 2018). The paracrine function of MSCs plays a major role in chondrocyte cellular processes including for examples:

- Expression of collagen type II and aggrecan could be increased while catabolic markers could be decreased by exposure to MSCs exosomes (Mianehsaz et al., 2019).
- Thrombospondin 2, a cartilage regulator, is secreted by MSCs and participates in the cartilage regeneration (Hankenson & Bornstein, 2002)
- Chondrocytes treated with MSCs exosomes upregulate the expression of anti-apoptosis gene like Survivin and Bcl-2 (S. Zhang et al., 2018)

2.5. Conclusions

Cell therapy based on mesenchymal stem cells is a promising approach to treat OA disease. This regenerative effect is mostly explained by the paracrine capacity of mesenchymal stem cells. However, cell therapy is influenced by several factors concerning the preparation and the way of administration of this product. It is therefore important to characterize the type of MSCs used in most relevant models of the disease studied.

4.5.2. Supernatant analysis in serum-free medium

mdMSCs were classically cultured in T80 flasks until 70% of confluency like described in the part 3.4.1 (differentiation of mdMSCs to chondrocytes). At this time, mdMSCs were cultured with 15mL of StemPro MSC serum-free medium (SFM) (Gibco) for 24 hours after 3 washes with PBS. Supernatant was then harvested and centrifuged (5', 1000rpm at RT) to remove cell debris. Proteins of the supernatant were obtained after trichloroacetic acid (TCA)/acetone precipitation. Briefly, the protocol consists in mixing supernatant, ice-cold acetone and TCA respectively in a 1:8:1 ratio. After a one-hour step at -20°C for precipitation, the sample was centrifuged at 11,500 rpm for 15 minutes. The supernatant was discarded and the pellet was washed with ice-cold acetone. The pellet of proteins was dissolved with buffer (urea 7M, thiourea 2M, CHAPS 1%, ASB14 1%, Tris 30mM, SDS 1% at pH 8.5) and a protein dosage (Pierce assay) was performed before processing for MS analysis like described in the part 3.4.2 (mass spectrometry analysis).

4.5.3. Supernatant analysis in DMEM F12

Cells were cultured in T150cm² flasks and the medium was changed at 60% confluency. Medium replacement was done with 15ml DMEM F12 without FBS supplementation and after 3 washes of cells with PBS. After 48 hours, the supernatant was harvested, centrifuged to remove cell debris and then filtered with Amicon Ultracel 3k (UFC900324) (centrifuged twice for 30 minutes at 4000 rpm and at 4°C). Protein concentration of the concentrated sample was then assessed before processing for MS analysis.

4.5.4. *In vitro* osteoarthritis model

TNF α (1 ng/mL) (Bio-Techne, 210-TA) and IL-1 β (0.1 ng/mL) (Bio-Techne, 201-LB) added to cell culture medium (DMEM F12) constitute the hereafter called “inflammatory medium”.

4.5.5. Cell culture for SILAC experiment

Equine mesenchymal stem cells, obtained from RevaTis (Belgium), were harvested from muscle as previously described (Ceusters et al., 2017). They were cultured in DMEM F-12 medium supplemented with 20 % of fetal bovine serum, 100 IU/mL of penicillin-streptomycin and 0.5 % of amphotericin B according to manufacturer's instructions. mdMSCs were seeded at 10,000 cells/cm² and harvested at 90 % of confluency. Cells are not cultured beyond passage 6 and medium was changed every 2 to 3 days. The SILAC experiment was conducted with biological material from 3 different donors for mdMSCs and 3 other donors for cartilage.

mdMSCs as a drug delivery device

5. *mdMSCs as a drug delivery device*

5.1. Introduction

Curcumin, also known as diferuloylmethane, is a polyphenolic nutraceutical isolated from the roots of *Curcuma longa* (Abdollahi, Momtazi, Johnston, & Sahebkar, 2018). Curcumin is the major curcuminoid present in turmeric (Gupta et al., 2013) at a concentration of 2-5% in dried turmeric powder (Nakagawa et al., 2014).

Traditional Indian and Chinese medicines use this spice to treat inflammatory diseases for thousands of years (Priyadarsini, 2009). Curcumin is a hot topic with over 15 000 manuscripts related to the biological interactions and effects of curcumin (Nelson et al., 2017). The first medical effect of curcumin was published in 1937 and concerned the treatment of cholecystitis in human (Oppenheimer, 1937). In veterinary medicine, first publications supporting pharmacological activities of curcumin were published in the 90s (Lans & Brown, 1998).

Various biological effects of curcumin are conferred by its ability to modulate multiple cell signalling molecules (Gupta et al., 2013). Curcumin act as an anti-inflammatory molecule by inhibiting the activation of NF κ B and the nitric oxide synthase (iNOS) enzyme (Alves et al., 2019).

The inhibition of NF κ B leads to a down-regulated expression of pro-inflammatory cytokines such as Interleukin (IL)-1, IL-6, IL-8 and TNF- α (Y. Wang, Tang, Duan, & Yang, 2018). *In vitro* cytotoxicity of curcumin was reported for doses superior than 25 μ M of curcumin for 48 hours (J. Zhao, Sun, Ye, & Tian, 2011).

Antioxidant properties of curcumin result from the structure of the molecule that confers an excellent electron transfer capability (Barzegar & Moosavi-Movahedi, 2011). The chemical structure of curcumin is two methoxy phenols attached symmetrically which confers photophysical and photochemical properties (figure 23) (Priyadarsini, 2009).




Figure 23: Chemical curcumin structure (A). Curcumin surrounded by 2 cyclodextrin complexes (B) (Priyadarsini, 2009).

Curcumin is widely studied as nutraceutical for osteoarthritis disease. Positive effects on pain and joint stiffness are described after an oral treatment with curcumin (Zeng, Yang, Hao, Yu, & Chen, 2021). Intra-articular injection of curcumin is also effective to decrease the inflammatory response induced by

OA: curcumin downregulates the expression of TLR4 and the NFκB pathway (D. Yan, He, Guo, Li, & Wang, 2019).

Despite its many biological effects, the major disadvantages of curcumin are its very poor water solubility and systemic bioavailability (Priyadarsini, 2009). The chemical instability (Metzler, Pfeiffer, Schulz, & Dempe, 2013) and the lipophilic nature of this molecule are responsible of these drawbacks. Curcumin is soluble in organic solvents like ethanol, methanol, dimethyl sulfoxide-acetone and others. The stability of curcumin is another concern : *in vitro* studies showed degradation up to 90% in physiological solution after one hour (Alves et al., 2019).

The European Food Safety Authority Panel set the acceptable daily dose of curcumin: 3mg/kg bodyweight (Alves et al., 2019). Human patients with pancreatic cancer were treated with 8g/day of curcumin and this polyphenol was safe and well tolerated (Dhillon et al., 2008). A negligible absorption and a low bioavailability explain the rare side effects of curcumin even when administered at high oral dose (Nelson et al., 2017).

Various strategies have been employed to increase this polyphenol bioavailability and to take advantages of its pharmaceutical effects: using adjuvants, nanoparticles, liposomes, micelles, phospholipid complexes or by changing the route of administration (Kunnumakkara et al., 2017). Using curcumin as an efficient drug is a challenge to develop a good drug candidate with properties like chemical stability, high water solubility, potent and selective target activity, high bioavailability, broad tissue distribution, stable metabolism and low toxicity (Nelson et al., 2017).

To associate cell therapy with curcumin, treatment of stem cells has been studied and showed different effects on mesenchymal properties. First, curcumin interacts with cell membrane proteins of MSCs and can activate or suppress different signaling pathways, such as Wnt or NFκB signaling pathways influencing the differentiation of MSCs into the three mesodermal lineages (Gorabi et al., 2019). Then, curcumin pre-treatment is an approach to increase the viability of MSCs during transplantation by the improvement of mitochondrial function (X. Wang et al., 2019).

The present study is focused on a water-soluble derivative of curcumin called NDS27 which is a hydroxypropyl-beta-cyclodextrin (HPβCD) complex of curcumin lysinate. Indeed, NDS27 is about 33,000 times more soluble in water than synthetic curcumin (WO/2009/144220, 2009). In addition, cyclodextrin complexes could improve the penetration of curcumin into cells compared to the native form (Derochette et al., 2014). The goal of this association is to increase the immuno-modulatory capacity of mdMSCs with a derivative curcumin form by acting on antioxidant and paracrine properties in inflammatory conditions. Previous study shows that NDS27 is able to inhibit superoxide anion production by neutrophils (Franck et al., 2019). The association between MSCs harvested in muscle

with minimally invasive process and a curcumin derivative, that does not require any organic solvent to be dissolved, may lead to a new therapeutic tool suitable for clinical application. The characterization of this cellular product was described in the publication (Colin et al., 2021) listed below. This cryopreserved product was developed to be used intra-articularly in horses joint suffering from OA and injected directly post thawing.

5.2. mdMSCs as drug carrier for NDS27



Received: 11 December 2020 | Revised: 27 January 2021 | Accepted: 8 February 2021

DOI: 10.1111/jcmm.16403

SHORT COMMUNICATION

WILEY

Priming of mesenchymal stem cells with a hydrosoluble form of curcumin allows keeping their mesenchymal properties for cell-based therapy development

Margaux Colin^{1,2} | Lola Dechêne^{3,4} | Justine Ceusters⁵ | Ariane Niesten⁵ | Catherine Demazy⁴ | Laurence Lagneaux⁶ | Karim Zouaoui Boudjeltia⁷ | Thierry Franck⁵ | Pierre Van Antwerpen² | Patricia Renard⁴ | Véronique Mathieu¹ | Didier Serteyn^{3,5}

¹Department of Pharmacotherapy and Pharmaceuticals, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Brussels, Belgium

²RD3- Pharmacognosy, Bioanalysis and Drug Discovery Unit and Analytical Platform, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Brussels, Belgium

³Department of Clinical Sciences, Anaesthesiology and Equine Surgery, Faculty of Veterinary Medicine, B41, University of Liege, Sart Tilman, Liège, Belgium

⁴Unité de Recherche en Biologie Cellulaire (URBC) - Namur Research Institute for Life Sciences (Narilis), University of Namur (UNamur), Namur, Belgium

⁵Centre of Oxygen, Research and Development, Institute of Chemistry B6a, University of Liege (ULiège), Sart Tilman, Liège, Belgium

⁶Laboratory of Clinical Cell Therapy, ULB-Research Cancer Center (U-CRC), Jules Bordet Institute, Université libre de Bruxelles (ULB), Brussels, Belgium

⁷Laboratory of Experimental Medicine, Université libre de Bruxelles, CHU de Charleroi, Hôpital Vésale, Montigny-le-Tilleul, Belgium

Correspondence

Didier Serteyn, Department of Clinical Sciences, Anaesthesiology and Equine Surgery, Faculty of Veterinary Medicine, B41, University of Liege, Sart Tilman, 4000 Liège, Belgium.
Email: didier.serteyn@uliege.be

Funding information

Service Public de Wallonie, Grant/Award Number: WALInnov program and convention number 1610151; Fondation Universitaire de Belgique

Abstract

Mesenchymal stem cells are increasingly studied for their use as drug-carrier in addition to their intrinsic potential for regenerative medicine. They could be used to transport molecules with a poor bioavailability such as curcumin in order to improve their clinical usage. This natural polyphenol, well-known for its antioxidant and anti-inflammatory properties, has a poor solubility that limits its clinical potential. For this purpose, the use of NDS27, a curcumin salt complexed with hydroxypropyl-beta-cyclodextrin (HPβCD), displaying an increased solubility in aqueous solution, is preferred. This study aims to evaluate the uptake of NDS27 into skeletal muscle-derived mesenchymal stem cells (mdMSCs) and the effects of such uptake onto their mesenchymal properties. It appeared that the uptake of NDS27 into mdMSCs is concentration-dependent and not time-dependent. The use of a concentration of 7 μmol/L which does not affect the viability and proliferation also allows preservation of their adhesion, invasion and T cell immunomodulatory abilities.

KEYWORDS

curcumin, cyclodextrin, equine MSCs, mdMSC, mesenchymal stem cells, mitochondria, NDS27

Margaux Colin and Lola Dechêne should be considered joint first authors

Didier Serteyn and Véronique Mathieu should be considered joint senior authors

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. *Journal of Cellular and Molecular Medicine* published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

J Cell Mol Med. 2021;00:1–5.

wileyonlinelibrary.com/journal/jcmm | 1

1 | INTRODUCTION

Mesenchymal stem cells (MSCs) are multipotent stem cells implicated in homeostasis and tissue repair.¹ Curcumin, a polyphenol extracted from the roots of *Curcuma Longa* L., is used to treat notably inflammatory diseases for thousands of years.^{2,3} The major disadvantages of curcumin are its very poor water solubility and its low systemic bioavailability.³ The present study is therefore focused on a hydroxypropyl-beta-cyclodextrin (HP β CD) complex of curcumin lysinate called NDS27, which is about 33 000 times more soluble in water than synthetic curcumin.⁴ The association of MSCs with a complex of curcumin that does not require any solvent to be

dissolved, may lead to a new therapeutic tool suitable for clinical application. Thus, this study aims to evaluate (a) the cellular toxicity of the NDS27 on MSCs, (b) the uptake and subcellular localization of NDS27 and (c) the effects of such loading (ie uptake) on mitochondrial function and mesenchymal properties of skeletal muscle-derived MSCs (mdMSCs).

2 | MATERIALS AND METHODS

Detailed materials and methods are provided in the Appendix S1 section.




FIGURE 1 Internalization of NDS27 and synthetic curcumin by equine mdMSCs. (A) Average IC_{50} of synthetic curcumin and NDS27 on equine mdMSC after 24, 48 or 72 h of treatment relative to untreated control. Data are expressed as mean \pm SD of five independent biological replicates. (B) Quantity of curcumin (ng) internalized in one million equine mdMSCs after 2, 4 or 6 h of treatment with NDS27 (7 or 42 μ mol/L) or synthetic curcumin (42 μ mol/L). Data are expressed as mean of three independent biological replicates \pm SD. (C) Micrographies of mdMSCs from donor 3 after their loading with NDS27 at 7 μ mol/L (green fluorescence; Ex: 488 nm; Em: between 502–576 nm) and staining with MitoTracker probe (red fluorescence; Ex: 561 nm; Em: between 572–636 nm) (magnification \times 400). The thin yellow lines present on the representative micrography is the transect used for the co-location evaluation. (D) Intensities of both green (NDS27) and red (MitoTracker) fluorescence for each point along the transect traced on the micrography shown in (C), indicating that NDS27 is partially co-located with MitoTracker and thus, mitochondria. The presented result was obtained on donor 3 and is representative of experiments conducted on two other donors. (E) Data from 5 different donors (at least 6 images/donor) were quantified to assess the correlation of co-location between natural fluorescence of NDS27 and MitoTracker probe using Pearson coefficient method. The correlation between NDS27 and MitoTracker is significantly distinct from the correlation between NDS27 and control condition (consisting in micrography of MitoTracker probe rotated of 90°) suggesting that the mitochondrial co-location of NDS27 is not random. $P < .01$ (**)




FIGURE 2 Effects of NDS27 on mitochondrial function and mesenchymal stem cells properties. Cells were treated during 2 h with 7 $\mu\text{mol/L}$ of NDS27 or synthetic curcumin, or with 35 $\mu\text{mol/L}$ of HP β CD. (A) Effect of treatments on respiration complexes (I and II) activity. Data are expressed as Flux Control Ratio \pm SD. The experiment was performed on three independent biological replicates. (B) Intracellular ROS and RNS content in mdMSCs one or 24 h after the loading. Data are expressed as mean \pm SD of five biological replicates. Statistical comparisons between treated conditions and control 1 h after loading are based on Mann-Whitney test according to conventional thresholds: $P < .05$ (*). (C) Mitochondrial ROS abundance in mdMSCs 30 min after the loading and 24 h later. Data are expressed as mean \pm SD of five biological replicates. (D) Mitochondrial membrane potential in mdMSCs 1 h after the loading and 24 h later. Data are expressed as mean \pm SD of five biological replicates. (E) Cell adhesion capacity of mdMSCs 1 h after treatments. Data are expressed as mean of OD at 570 nm \pm SD of two independent biological replicates analysed in four technical replicates. (F) Percentage of invasive mdMSCs, 24 h after the treatments. Data are expressed as mean of percentage of invasive cells \pm SD of two biological replicates analysed each in five technical replicates. (G) Percentage of inhibition of T cell proliferation \pm SD mediated by NDS27-loaded mdMSCs at different cellular ratios. The experiment was performed on five biological replicates.

3 | RESULTS AND DISCUSSION

This *in vitro* study was specifically designed to evaluate the impact of NDS27 loading on equine mdMSCs in the aim to develop curcumin-loaded mdMSCs. This new therapeutic association would allow

possibly benefiting from both mdMSCs regenerative therapy and curcumin effects to treat inflammatory diseases.

Firstly, we showed that the average concentrations of NDS27 and synthetic curcumin required to inhibit by 50% the cell growth (IC_{50}) of mdMSCs are both of approximately 50 $\mu\text{mol/L}$ after 24 hours and

dropped to 27 $\mu\text{mol/L}$ after 48 and 72 hours of treatment (Figure 1A). mdMSCs appeared thus less sensitive to cytotoxic effects of curcumin than cancerous cell lines (mean IC_{50} of 7.85 $\mu\text{mol/L}$; NCI database). Moreover, Wang *et al* have demonstrated benefits of a pre-treatment of rat bone-marrow MSCs with curcumin (10 $\mu\text{mol/L}$ for 24 hours) on their survival from hypoxia/reoxygenation injury which is a phenomenon that can be encountered during their use for regenerative medicine.⁵ As shown in Appendix S1, continuous exposure to a 7 $\mu\text{mol/L}$ NDS27 treatment provoked limited morphological alterations and only a moderate decreased proliferation of mdMSCs (Figure S1). Because we intend to prime mdMSCs for few hours only and because videomicroscopy analysis showed limited morphological changes of the cells till 24 hours even at high concentration (Figure S1A), we decided to evaluate the internalization of NDS27 in mdMSCs at two working concentrations: a low concentration that appeared non-toxic, ie 7 $\mu\text{mol/L}$, and a concentration of 42 $\mu\text{mol/L}$ which is close to the average 24 hours IC_{50} . Quantities of curcumin internalized by the cells are concentration-dependent: approximately 2% of the initial dose put in presence of cells is internalized whatever the duration of exposure duration or the form of curcumin (ie NDS27 or synthetic curcumin) (Figure 1B). Similarly, Moustapha *et al* who quantified the uptake of curcumin in a human liver cell line demonstrated that the internalization of curcumin is indeed already maximal after 5 minutes.⁶ The assessment of the viability and proliferation capacities of pre-loaded mdMSCs revealed that a loading of 2 hours with 7 $\mu\text{mol/L}$ of NDS27 does not affect these properties (Table S3). Therefore, we selected this priming condition for further investigations. We took advantage of the intrinsic fluorescence of curcumin to observe its subcellular localization under these experimental conditions. A cytosolic punctuate pattern suggested a mitochondrial localization, which was confirmed by observing the partial colocalization of curcumin with MitoTracker, a mitochondria-specific probe (Figure 1C,D,E). This observation, in concordance with other studies⁷ prompted us to assess if NDS27 could modify mitochondrial functions. Indeed, mitochondrial activity could influence the undifferentiated state of MSCs and their differentiation potential.⁹ Although a slight increase in total and mitochondrial ROS levels and a slight drop of the mitochondrial membrane potential were observed just after the loading of mdMSCs with 7 $\mu\text{mol/L}$ of curcumin or NDS27 (Figure 2B,C,D), high resolution respirometry did not evidence any significant impact on mitochondrial respiration and especially the oxygen consumption for complexes I and II (Figure 2A). In addition, the effects observed on ROS production and mitochondrial membrane potential appeared transient as they did not persist 24 hours after the loading (Figure 2B,C,D).

One of the potential clinical applications of NDS27-loaded mdMSCs could be osteoarthritis that would benefit from the anti-inflammatory properties of curcumin as well as immunomodulatory and regenerative properties of MSCs. For this purpose, the preservation of mesenchymal properties like their adhesion to cartilage and their immunomodulation potential is essential.^{10,11} We observed herein that adhesion of mdMSCs to fibronectin is very rapid and already complete after 1 hour (Figure S2). Furthermore, the capacity

of mdMSCs to adhere to fibronectin was not affected by their loading with NDS27 (Figure 2E). For reparative cell therapy, after their adhesion to cartilage, mdMSCs have to invade the injured cartilage to ensure the structural and functional maintenance.¹² The evaluation of the invasive capacity of mdMSCs loaded 2 hours with NDS27 at 7 $\mu\text{mol/L}$ showed that the NDS27 loading does not affect the invasiveness of mdMSCs (Figure 2F). Moreover, the expression of mesenchymal surface markers (CD29, CD44, CD73 and CD105) and a pluripotency marker (OCT4) 24, 48 and 72 hours after the loading was also not altered by this loading (Figure S3). Finally, the potential of NDS27-treated mdMSCs to inhibit T cell proliferation for 24 hours was intact whatever the mdMSCs/T cells ratio (Figure 2G). Importantly, previous studies have nevertheless demonstrated cytoprotective effects of curcumin pre-treatment (10 $\mu\text{mol/L}$ for 24 hours) on rat bone-marrow- and adipose tissue-MSCs against oxidative stress induced by H_2O_2 exposure thanks to its antioxidant properties.^{13,14} Although the effects of NDS27 observed in the present work are similar to those of synthetic curcumin, NDS27 displays a real advantage as it is water-soluble compared to curcumin that needs to be dissolved in DMSO.

In conclusion, we found that curcumin loading of mdMSCs is concentration-dependent and that a short priming of only 2 hours at 7 $\mu\text{mol/L}$ of NDS27 as well as curcumin itself does not alter their mitochondrial function and allows keeping their mesenchymal properties. Altogether, those data illustrate the safety of NDS27 as a curcumin loading agent and allow us to consider the immediate perspectives that include evaluation of the anti-inflammatory, antioxidant and immunomodulatory properties of NDS27-loaded mdMSCs in osteoarthritis models.

ACKNOWLEDGEMENTS

This work was supported by the grant WALLInnov program from Wallonie recherche SPW, convention number 1610151. This publication was supported by the 'Fondation Universitaire de Belgique'.

CONFLICT OF INTEREST

VM and DS are inventors of NDS27 (WO2009144220A1). DS and JC got patent for mdMSC (WO2015091210). DS is administrator of BiopTis and RevaTis companies (respectively provider of NDS27 and mdMSCs). JC and AN are employees in RevaTis. Other authors have no conflict of interest.

AUTHOR CONTRIBUTION

Margaux Colin: Data curation (equal); Formal analysis (equal); Investigation (equal); Writing-original draft (equal). **Lola Dechéne:** Data curation (equal); Formal analysis (equal); Investigation (equal); Writing-original draft (equal). **Justine Ceusters:** Funding acquisition (equal). **Ariane Niesten:** Resources (supporting). **Catherine Demazy:** Resources (supporting). **Laurence Lagneaux:** Methodology (supporting). **Karim Zouaoui Boudjeltia:** Writing-review & editing (equal). **Thierry Franck:** Project administration (equal); Writing-review & editing (equal). **Pierre Van Antwerpen:** Writing-review & editing (equal). **Patricia Renard:** Conceptualization (equal); Supervision (equal);

Validation (equal); Writing-review & editing (equal). **Véronique Mathieu**: Conceptualization (equal); Supervision (equal); Validation (equal); Writing-review & editing (equal). **Didier Serteyn**: Funding acquisition (equal); Writing-review & editing (equal).

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Lola Dechêne  <https://orcid.org/0000-0002-1624-2202>

REFERENCES

- Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. *Int J Mol Sci*. 2017;18(9):1852.
- Abdollahi E, Momtazi AA, Johnston TP, Sahebkar A. Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: a nature-made jack-of-all-trades? *J Cell Physiol*. 2018;233(2):830-848.
- Priyadarsini KI. Photophysics, photochemistry and photobiology of curcumin: studies from organic solutions, bio-mimetics and living cells. *J Photochem Photobiol C Photochem Rev*. 2009;10(2):81-95.
- Neven P, Serteyn D, Delarge J, et al. Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy. December 2009.
- Wang X, Zhang Y, Yang Y, et al. Curcumin pretreatment protects against hypoxia/reoxygenation injury via improvement of mitochondrial function, destabilization of HIF-1 α and activation of Epac1-Akt pathway in rat bone marrow mesenchymal stem cells. *Biomed Pharmacother*. 2019;109(127):1268-1275.
- Moustapha A, Pérétout P, Rainey N, et al. Curcumin induces cross-talk between autophagy and apoptosis mediated by calcium release from the endoplasmic reticulum, lysosomal destabilization and mitochondrial events. *Cell Death Discov*. 2015;1:15017.
- Jiang S, Zhu R, He X, et al. Enhanced photocytotoxicity of curcumin delivered by solid lipid nanoparticles. *Int J Nanomedicine*. 2017;12:167-178.
- Szebeni GJ, Balázs Á, Madarász I, et al. Achiral Mannich-base curcumin analogs induce unfolded protein response and mitochondrial membrane depolarization in PANC-1 cells. *Int J Mol Sci*. 2017;18(10):2105.
- Li Q, Gao Z, Chen Y, Guan M-X. MINI-REVIEW the role of mitochondria in osteogenic, adipogenic and chondrogenic differentiation of mesenchymal stem cells. *Protein Cell*. 2017;8(6):439-445.
- Hung BP, Babalola OM, Bonassar LJ. Quantitative characterization of mesenchymal stem cell adhesion to the articular cartilage surface. *J Biomed Mater Res - Part A*. 2013;101(12):3592-3598.
- Wiredu Ocansey DK, Pei B, Yan Y, et al. Improved therapeutics of modified mesenchymal stem cells: an update. *J Transl Med*. 2020;18(1):42.
- Soliman S. Mesenchymal cells in cartilage growth, regeneration and replacement. *J Histol Histopathol Res*. 2017;1(1):6-7.
- Liu J, Zhu P, Song P, et al. Pretreatment of adipose derived stem cells with curcumin facilitates myocardial recovery via antiapoptosis and angiogenesis. *Stem Cells Int*. 2015;2015:1-12.
- Wang N, Wang F, Gao Y, et al. Curcumin protects human adipose-derived mesenchymal stem cells against oxidative stress-induced inhibition of osteogenesis. *J Pharmacol Sci*. 2016;132(3):192-200.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Colin M, Dechêne L, Ceusters J, et al. Priming of mesenchymal stem cells with a hydrosoluble form of curcumin allows keeping their mesenchymal properties for cell-based therapy development. *J Cell Mol Med*. 2021;00:1-5. <https://doi.org/10.1111/jcmm.16403>

Supporting Information

1. Materials and methods

All culture materials, reagent and equipment sources are detailed in Key resources tables (section 1.13).

1.1 Cell lines and compounds

The equine skeletal mdMSCs from five donors (see section 1.13 Key resources table) were provided by RevaTis (Aye, Belgium). They were cultured in Dulbecco's modified Eagle's medium (DMEM) F-12 culture medium supplemented with 20% heat-inactivated fetal bovine serum (HI-FBS), 100 IU/mL of penicillin-streptomycin and 0.5% of amphotericin B at 37°C and 5% CO₂ according to the recommendations of RevaTis.¹

NDS27, synthetic curcumin and HPβCD were provided from BiopTis (Aye, Belgium). NDS27 and curcumin were respectively dissolved in water and dimethyl sulfoxide (DMSO) as described by Franck *et al.*²

1.2 Quantitative videomicroscopy

Computer-assisted phase contrast microscopy was performed as previously described.³ Briefly, mdMSCs were seeded in 25 cm² culture flasks and left untreated or treated with NDS27 at 7 μM. Pictures of one field were taken every four minutes during a 72 hours period and further compiled into a short movie. Quantitatively, global growth ratio was determined based on cell counting of pictures corresponding to 12, 24, 36 and 48 hours in comparison to time zero.

1.3 Quantification of intracellular curcumin by HPLC

Cells were treated with NDS27 at 7 or 42 μM, or with synthetic curcumin at 42 μM for two, four or six hours and were then washed twice with Dulbecco's phosphate-buffered saline (DPBS), scrapped in 100 μL of ice-cold methanol and sonicated for 30 seconds. Samples were then centrifuged five minutes at 12,000 g before analysis. The number of cells was determined for each condition to normalize the data of internalization for one million cells. Twenty microliters from the prepared samples were injected into the liquid chromatography system. Analyses were performed with a high-performance liquid chromatography (HPLC) 1100 series. Separation was performed on a Discovery

C18 HPLC column (15 cm x 4.6 mm, 5 μ m particle size) using 0.2% trifluoroacetic acid acidified water / acetonitrile gradient (Table S1) at a flow rate of 1.0 mL/minute. The detection system was fixed at 425 nm. Data were acquired and integrated using Agilent Chemstation software. The data collected by the chromatographic system were analyzed on the basis of the peak area compared to a standard curve ranging from 1 to 25 μ M performed for each experiment with both NDS27 and synthetic curcumin.

Table S1. Sequence of gradient solvent to separate curcumin on Discovery C18 HPLC column.

Time (min)	Trifluoroacetic acid (%)	Acetonitrile (%)	Flow rate (mL/min)
0	70	30	1
2.5	70	30	1
11.5	10	90	1
12	70	30	1
14	70	30	1

1.4 Subcellular localization

Cells seeded in chambered coverglass Nunc Lab-Tek were treated with 7 μ M of NDS27 for 90 minutes 24 hours after the seeding. Then, DMEM-F12 without serum supplementation but containing 7 μ M of NDS27 and 100 nM of MitoTracker Red CM-H2XRos replaced the previous medium for 30 minutes to reach two hours of exposure. Cells were washed with DPBS and observed by confocal microscopy (SP5, Leica). Transects were obtained with Fiji software: lines were traced, analyzed with “plot profile” and added to the region of interest (ROI) manager to apply this line on the other fluorescence channel. Quantification of colocalization between NDS27 natural fluorescence and mitochondria probe was performed with Fiji software following the protocol of Dunn *et al.*⁴

1.5 Viability and proliferation assays

For each viability assay, cells were seeded in 96 well plates and were grown for 24 hours. To determine the half maximal inhibitory concentration (IC₅₀) of the products, cells were treated with NDS27 or synthetic curcumin at concentrations ranging from 10 nM to 100 μ M or left untreated for 24, 48 and 72 hours.

To evaluate the capacity of NDS27/curcumin-loaded mdMSCs (i.e. treated) to proliferate, cells were first exposed for two hours to 7 or 42 μ M of NDS27 or synthetic curcumin, 35 or 210 μ M of HP β CD or left untreated. After this loading treatment, cells

were washed once with culture medium and then incubated with culture medium for 24, 48 and 72 additional hours prior to viability evaluation.

1.5.1 MTT colorimetric assay

Cell viability based on a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay was performed as described previously.⁵ The viability was estimated using MTT that measured mitochondrial reduction into formazan at 570 nm with a spectrophotometer 680XR (reference wavelength 610 nm).

1.5.2 Sulforhodamine B Cell Cytotoxicity assay

This assay was performed according to the kit instructions. Briefly, at the end of the incubation period, cells were fixed and then stained with Sulforhodamine B (SRB) reagent for 15 minutes prior to the extraction of the colored product. Finally, the absorbance was measured at 570 nm with a microplate spectrophotometer Synergy Mx.

1.5.3 Crystal Violet assay

At the end of the incubation period, cells were fixed with 17.5% formaldehyde for 10 minutes at 4°C prior to their wash with distilled water. Plates were then dried before the addition of 0.1% crystal violet (CV) dissolved in methanol for 15 minutes at room temperature in the dark. After the coloration step, cells were washed with distilled water before the extraction of the colored product with acetic acid solution 33%. The absorbance was measured at 570 nm with a microplate spectrophotometer Synergy Mx.

1.6 Mitochondrial respiratory capacity

Cells were treated with NDS27, curcumin or HP β CD for 2 hours and then harvested for mitochondrial-respiratory capacity assay. The substrate-uncoupler-inhibitor titration (SUIT) protocol 1 was applied for the evaluation of mitochondrial respiration as described by Votion *et al.*⁶ Measures were recorded by high-resolution respirometry (Oxygraph-2k chamber, Oroboros instrument). Flux control ratio (FCR) was calculated as previously described.⁷

1.7 Measurement of total reactive oxygen species (ROS) and reactive nitrogen species (RNS), mitochondrial ROS and evaluation of mitochondrial membrane potential

For each of the three assays below, seeded cells were treated during two hours with NDS27 (7 μ M), synthetic curcumin (7 μ M), HPBCD (35 μ M), DMSO (0.07%), or left untreated. Cells were then washed once with culture medium prior to the addition of the probes. Analyses were performed either directly after the loading or 24 hours later. For this later condition, cells were washed once with culture medium and then left in culture medium for 24 hours before staining described below. Analyses of the samples were conducted on a total of 10,000 events for each sample with a Beckman Gallios cytometer.

1.7.1 Total ROS and RNS measurement

Intracellular amount of total ROS and RNS has been evaluated using the diacetylated form of 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA). ROS and RNS oxidize DFCH into 2',7'-dichlorofluorescein (DCF) which emits a green fluorescence measured by flow cytometry.⁸ Following the wash of cells, DCFH-DA (20 μ M) prepared in DPBS was added for one hour. Cells were then detached, centrifuged and resuspended in DPBS before the fluorescence analysis by flow cytometry.

1.7.2 Mitochondrial ROS measurement

The production of mitochondrial ROS including superoxide anions has been studied using the MitoSOX reagent.⁹ Following the wash of cells, MitoSOX (1 μ M) prepared in DPBS was added for 30 minutes. Cells were then detached, centrifuged and resuspended in DPBS before the fluorescence analysis by flow cytometry.

1.7.3 Mitochondrial membrane potential

The evaluation of the integrity of the mitochondrial membrane potential was performed using a cationic fluorescent dye: 1,1',3,3'-tetraethylbenzamidazolocarboxyanin iodide (JC-1) that concentrates into the mitochondria leading to aggregates that fluoresce in red (Emission: 590 nm). This process is impaired when the mitochondrial membrane potential is altered, and JC-1 remains in monomers that fluoresce in green (Emission: 529 nm).¹⁰ Directly after their loading or 24 hours later, cells were detached and centrifuged. Then, cells were stained with the JC-1 probe prepared in DPBS at 3.45 μ g/mL for 20 minutes. After two washes with DPBS, cells were resuspended in 150 μ L

of DPBS for fluorescence analyses. The red/green fluorescence ratio indicates the mitochondrial membrane potential.¹⁰

1.8 Cellular adhesion capacity

Cells pre-treated for two hours with curcumin or NDS27 at 7 μ M were seeded in 96 wells plates previously coated with human plasma fibronectin (0.2 mg/mL in DPBS). They were allowed to adhere for one and 21 hours at 37°C and 5% CO₂. After each time point, cells were washed once with DPBS and fixed with 17.5% formaldehyde for 10 minutes at 4°C prior to two washing steps with DPBS. Plates were dried before crystal violet staining with 0.1% crystal violet dissolved in methanol for 15 minutes at room temperature in the dark. Wells were then washed with distilled water before the extraction of the colored product with acetic acid solution 33%. The absorbance was measured at 570 nm with a microplate spectrophotometer Synergy Mx.

1.9 Cellular invasion capacity

Invasion ability of mdMSCs was studied *in vitro* using fibronectin-coated (0.2 mg/mL) Boyden invasion chambers (96 well plates; PromoKine). Cells pre-treated for two hours with curcumin or NDS27 at 7 μ M were seeded in top chamber in culture medium supplemented with 0.5% HI-FBS while the bottom chambers contained culture medium supplemented with 10% HI-FBS. After 24 hours incubation, the upper parts of the top chambers were washed with a Q-tip to remove cells that did not migrate. Cells having passed the fibronectin matrix and the polyethylene terephthalate membrane were then dissociated and stained according to manufacturer's instruction. Finally, the percentage of invasion was determined using a standard curve of seven points from 100,000 to 1,562 cells.

1.10 T-cell proliferation assays

This assay measures the ability of mdMSCs to inhibit the proliferation of purified T-lymphocytes. This immunomodulation property of mdMSCs were evaluated as previously described.^{1,11}

1.11 Real-time quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted using ReliaPrep RNA Miniprep Systems. Two micrograms of total RNA were reverse transcribed using GoScript Reverse Transcription mix

Oligo(dT) for cDNA synthesis. GoTaq qPCR Master Mix was then used to perform amplification on a Vii7 equipment. Primers listed in table S2 were used at a concentration of 300 nM. All results were normalized to the mRNA abundance of enolase (i.e. housekeeping gene) using the $2^{-\Delta\Delta Ct}$ method and expressed relative to the untreated cells condition.

Table S2. Primers used for RT-qPCR.

Primers			
Gene	Forward	Reverse	Efficiency (%)
Enolase	GTGCAGCCAACCTTCAGTGAA	CCAGCTTTCCCAATGGCATT	97
CD29	AGAATGTATACAAGCAGGGCCA	TTATATCTTTGGAGCCTCTGGG	93
CD44 ¹²	CCCACGGATCTGAAACAAGTG	TTCTGGAATTTGAGGTCTCCGTAT	87
CD73 ¹²	GGGATTGTTGGATACACTTCAAAAAG	GCTGCAACGCAGTGATTCA	87
CD90	GGTCCTCTACTTATCCAGCTTCA	CCAGTTTGTCTCGGAGCACA	95
CD105 ¹³	GACGCCAATCACAACATACA	TCCACATAGGACGCTACGAC	85
OCT4 ¹⁴	GGTACGAGTGTGGTTCTGC	GTGCCAGGGGAAAGGATACC	88

1.12 Statistical analysis

Statistical analyses of subcellular localization were performed by Prism using a Mann-Whitney test. Statistical analyses of mitochondrial respiratory capacity and T-cell proliferation assays were performed by Prism using the unpaired T test. Statistical analyses of global growth ratio, total ROS and RNS, mitochondrial superoxide anion and mitochondrial membrane potential were performed by Statistica using Mann-Whitney test. Statistical analyses of RT-qPCR were performed by Prism using the Kruskal-Wallis test followed by the Dunn's multiple comparison.

1.13 Key resources tables

mdMSCs donors		
Number of the donor	Sex	Age at the time of collection
1	♀	22 years
2	♀	16 years
3	♀	13 years
4	♀	12 years
5	♀	10 years

Culture medium, culture supplement, chemicals, recombinant proteins and kits	
Reagent or resource	Source
DMEM/F-12	Gibco, Thermofisher, Dilbeek, Belgium
Heat-inactivated foetal bovine serum (HI-FBS)	
Penicillin-streptomycin	
Amphotericin B	
DPBS	
Methanol	VWR International, Oud-Heverlee, Belgium
Acetonitrile	
Dimethyl sulfoxide (DMSO)	
Trifluoroacetic acid	Sigma-Aldrich, Diegem, Belgium
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)	
Crystal violet (CV)	
2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA)	
Human plasma fibronectin	
MitoTracker Red CM-H2XRos	Invitrogen, Thermofisher, Dilbeek, Belgium
MitoSOX reagent	
Sulforhodamine B Cell Cytotoxicity assay	Abcam, Cambridge, United-Kingdom
1,1',3,3'-tetraethylbenzamidazolocarboyanin iodide (JC-1)	Enzo Life Sciences, Brussels, Belgium
Primers	IDT, Leuven, Belgium
Cell invasion assay kit, fibronectin, 8 µm, 96 well	PromoKine, Bio-connect, The Netherlands
ReliaPrep RNA Miniprep Systems	Promega Benelux, Leiden, The Netherlands
GoScript Reverse Transcription mix Oligo(dT)	
GoTaq qPCR Master Mix	

Culture materials	
Resource	Source
25 cm ² culture flasks	Sarstedt AG & CO, Nümbrecht, Germany
96 well plates	
Coverglass Nunc Lab-Tek	Thermofisher, Dilbeek, Belgium
Equipment	
Resource	Source
HPLC 1100 series	Agilent Technologies, Santa Clara, USA
Diode Array Detector G1315B	
Discovery C18 HPLC column (15 cm x 4,6 mm, 5 µm particle size)	Supelco Analytical, Sigma-Aldrich, Diegem, Belgium
confocal microscopy (TCS SP5 II)	Leica Microsystems, Wetzlar, Germany
Spectrophotometer 680XR	Bio-Rad Laboratories, Berkeley, CA, USA
Spectrophotometer Synergy Mx	BioTek, France
Oxygraph-2k chamber, Oroboros instrument	Oroboros instruments, Innsbruck, Austria
Flow cytometer	Gallios, Beckmann Coulter, Analis, Suarlee, Belgium
Odyssey Infrared Imager	Li-Cor Biosciences, Lincoln, NE, USA
Via7 equipment	Applied Biosystems, Thermo Fisher Scientific Leusden, The Netherlands
Software	
Resource	Source
Agilent Chemstation software	Agilent Technologies, Santa Clara, USA
Fiji software	National Institutes of Health, MD, USA
Odyssey V3.0 software	Li-Cor Biosciences, Lincoln, NE, USA
Statistica	Statsoft, Tulsa, OK, USA
Prism	GraphPad Software, San Diego, CA, USA

1.14 References

1. Ceusters J, Lejeune JP, Sandersen C, Niesten A, Lagneaux L, Serteyn D. From skeletal muscle to stem cells: An innovative and minimally-invasive process for multiple species. *Sci Rep*. 2017. doi:10.1038/s41598-017-00803-7
2. Franck T, Aldib I, Zouaoui Boudjeltia K, et al. The soluble curcumin derivative NDS27 inhibits superoxide anion production by neutrophils and acts as substrate and reversible inhibitor of myeloperoxidase. *Chem Biol Interact*. 2019;297:34-43. doi:10.1016/j.cbi.2018.10.008
3. Debeir O, Mégalizzi V, Warzée N, Kiss R, Decaestecker C. Videomicroscopic extraction of specific information on cell proliferation and migration in vitro. *Exp Cell Res*. 2008;314(16):2985-2998. doi:10.1016/j.yexcr.2008.06.010
4. Dunn KW, Kamocka MM, McDonald JH. A practical guide to evaluating colocalization in biological microscopy. *AJP Cell Physiol*. 2011;300(4):C723-C742. doi:10.1152/ajpcell.00462.2010
5. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J Immunol Methods*. 1983;65(1-2):55-63. doi:10.1016/0022-1759(83)90303-4
6. Votion DM, Gnaiger E, Lemieux H, Mouithys-Mickalad A, Serteyn D. Physical fitness and mitochondrial respiratory capacity in horse skeletal muscle. *PLoS One*. 2012;7(4). doi:10.1371/journal.pone.0034890
7. Pesta D, Gnaiger E. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. *Methods Mol Biol*. 2012;810:25-58. doi:10.1007/978-1-61779-382-0_3
8. Eruslanov E, Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry. *Methods Mol Biol*. 2010;594:57-72. doi:10.1007/978-1-60761-411-1_4
9. Kauffman M, Kauffman M, Traore K, et al. MitoSOX-Based Flow Cytometry for Detecting Mitochondrial ROS. *React Oxyg Species*. 2016;2(5). doi:10.20455/ros.2016.865
10. Elefantova K, Lakatos B, Kubickova J, Sulova Z, Breier A. Detection of the mitochondrial membrane potential by the cationic dye JC-1 in 11210 cells with massive overexpression of the plasma membrane ABCB1 drug transporter. *Int J Mol Sci*. 2018;19(7). doi:10.3390/ijms19071985
11. Fayyad-Kazan H, Faour WH, Badran B, Lagneaux L, Najjar M. The immunomodulatory properties of human bone marrow-derived mesenchymal stromal cells are defined according to multiple immunobiological criteria. *Inflamm Res*. 2016;65(6):501-510. doi:10.1007/s00011-016-0933-2
12. Barrachina L, Remacha AR, Romero A, et al. Effect of inflammatory environment on equine bone marrow derived mesenchymal stem cells immunogenicity and immunomodulatory properties. *Vet Immunol Immunopathol*. 2016. doi:10.1016/j.vetimm.2016.02.007
13. Zahedi M, Parham A, Dehghani H, Mehrjerdi HK. Stemness signature of equine marrow-derived mesenchymal stem cells. *Int J Stem Cells*. 2017. doi:10.15283/ijsc16036
14. Sharma R, Livesey MR, Wyllie DJA, et al. Generation of functional neurons from feeder-free, keratinocyte-derived equine induced pluripotent stem cells. *Stem Cells Dev*. 2014;23(13):1524-1534. doi:10.1089/scd.2013.0565

2. Supplementary results




Figure S1. (a) Illustration of the in vitro effects of NDS27 treatments at 7 and 35 µM on equine mdMSCs of donor 3, obtained by videomicroscopy. Figures are representative of one experiment performed in three replicates. (b) Global growth ratio, calculated from videomicroscopy analyses illustrated in (a) in equine mdMSCs cells after 12, 24, 36 and 48 hours treatments with NDS27 at 7 µM. Results are expressed as the mean growth ratio between treated cells relative to untreated control arbitrarily set to $1 \pm \text{SD}$ of three independent biological replicates. Statistical comparison between untreated cells and treated cells for each duration of treatment is based on Mann-Whitney test according to conventional thresholds: $p < 0.05$ (*).

	24h			48h			72h		
	MTT	CV	SRB	MTT	CV	SRB	MTT	CV	SRB
HPBCD 35 μ M	100 \pm 3	100 \pm 10	100 \pm 19	99 \pm 6	97 \pm 7	104 \pm 7	99 \pm 5	103 \pm 6	93 \pm 10
curcumin 7 μ M	105 \pm 5	95 \pm 9	110 \pm 36	112 \pm 9	93 \pm 12	118 \pm 13	110 \pm 7	92 \pm 18	104 \pm 16
NDS27 7 μ M	102 \pm 5	93 \pm 10	119 \pm 25	103 \pm 3	95 \pm 7	115 \pm 9	104 \pm 7	104 \pm 6	98 \pm 7
HPBCD 210 μ M	98 \pm 2	106 \pm 23	106 \pm 20	99 \pm 5	97 \pm 11	107 \pm 12	101 \pm 9	99 \pm 2	95 \pm 9
curcumin 42 μ M	102 \pm 8	81 \pm 6	102 \pm 18	91 \pm 13	67 \pm 17	108 \pm 10	101 \pm 9	71 \pm 21	87 \pm 13
NDS27 42 μ M	93 \pm 8	74 \pm 9	81 \pm 18	81 \pm 9	66 \pm 8	83 \pm 10	86 \pm 12	72 \pm 11	76 \pm 14

Table S3. Percentage of viable equine mdMSCs, obtained by MTT, crystal violet (CV) and SRB assay, 24 hours after the loading with NDS27 or synthetic curcumin at 7 or 42 μ M, or with HP β CD at 35 or 210 μ M. Data are expressed as the mean of viable cells relative to untreated cells (100 %) \pm SD of five biological replicates. Grey boxes highlight a decrease in cell growth of more than 20 %.




Figure S2. Cell adhesion capacity of untreated mdMSCs of donor 2 and 4, one and 21 hours after the seeding \pm SD of four technical replicates.




Figure S3. Effects of a two hours loading with NDS27 (7 μ M), synthetic curcumin (7 μ M) or HP β CD (35 μ M) on the expression of MSCs characteristic genes ((a) CD29, (b) CD44, (c) CD73, (d) CD90, (e) CD105 and (f) OCT4) measured by qPCR. Data are expressed in fold change to housekeeping gene (Enolase) \pm SD of three independent biological replicates.

5.3. Goals of this part

After showing that NDS27 could be internalized into mdMSCs, we want to study the scientific interest of this innovative cellular therapy product in an osteoarthritis model and after 24 hours, as survival of MSCs is described to concern a small percentage of injected cells (Kumar, Kadamb, & Kadamb, 2020). First, considering the mitochondrial sublocalization of NDS27, we will measure the impact of TNF α and IL-1 β on mitochondrial respiration of mdMSCs cultured for 24 hours in pro-inflammatory medium. Then, the protection conferring by NDS27 priming will be evaluated by measuring the pro-inflammatory gene expression of cells cultured with TNF α and IL-1 β . Finally, regarding the low internalization and protection conferred by NDS27, a new method of priming will be evaluated in terms of cellular viability and mitochondrial respiration.

5.4. Material & methods

5.4.1. Mitochondrial respiratory capacity

At 80% confluency, cells were treated with pro-inflammatory medium (TNF α 1 ng/mL and IL-1 β 0.1 ng/mL) for 24 hours. Cells were detached with trypsin, centrifuged (5' at 1000 rpm and at RT), counted and then resuspended in Mir05 media (110 mM sucrose, 60 mM K⁺-lactobionate, 0,5 mM EGTA, 3 mM MgCl₂, 20 mM taurine, 10 mM KH₂PO₄, 20 mM HEPES adjusted at pH 7,1 with KOH at 37 °C; and 1 g/L of BSA) (Gnaiger et al., 2000) before being placed in the chamber of high-resolution respirometry (Oxygraph-2k chamber, Oroboros instrument). A substrate-uncoupler-inhibitor titration (SUIT) protocol (table 14) was applied: after permeabilization with digitonin, electron flow through complex I was supported by the substrates glutamate, malate and pyruvate. ADP was added and permeabilization was tested with cytochrome C. Succinate was then used to support electron flow through complexes I and II. The maximal electron transfer system was obtained after by the titration of Trifluoromethoxy carbonylcyanide phenylhydrazone (FCCP), an uncoupler agent. Rotenone and antimycin A were finally used to obtain the residual oxygen consumption by respectively inhibiting complexes I and III.

Substrates/Inhibitors	Final concentration in Oroboros chamber	Site of action	Purpose
Digitonin (Fluka, 37008)	1.5 µg/mL	Membrane	Permeabilization
Malate (Sigma, M1000)	2 mM	Complex I	Electron donor
Glutamate (Sigma, G1626)	10 mM		
Pyruvate (Sigma, P2256)	5mM		
ADP (Sigma, S2378)	2,5 mM	Complex V	Oxidative phosphorylation saturation
Cytochrome C (Sigma, C7752)	10 µM	Complex IV	Evaluation of membrane integrity
Succinate (Sigma, S2378)	10 mM	Complex II	Electron donor
FCCP (Sigma, 04876)	2 x 0.5 µM	Membrane potential	Uncoupler
Rotenone (Sigma, R8875)	0.5 µM	Complex I	Inhibitor
Antimycin A (Sigma, A8674)	2.5 µM	Complex III	Inhibitor

Table 14: Substrates and inhibitors used for SUIT protocol applied to cells treated with pro-inflammatory media 24 hours previous the analysis (Votion, Gnaiger, Lemieux, Mouithys-Mickalad, & Serteyn, 2012).

Flux control ratio (FCR) was obtained as described by Pesta & Gnaiger: it is the mitochondrial respiration normalized for maximum flux and independently of mitochondrial content and cell size (Pesta & Gnaiger, 2012). Data was analyzed with Paired t test if data passed normality tests (D'Agostino & Pearson normality test, Shapiro-Wilk normality test and Kolmogorov-Smirnov test) or with Wilcoxon test if the data does not assume the Gaussian distribution

5.4.2. Flux analyzer

Respirometry analysis was performed with a Seahorse XFp extracellular flux analyzer (Agilent). Cells were seeded 48 hours prior to experiment at 5000 cells per well in an XFp mini-plate (Agilent). One day post seeding, the medium was changed and replaced with fresh one or with pro-inflammatory medium (TNF α 1 ng/mL and IL-1 β 0.1 ng/mL) for 24 hours. Then, cells were incubated with an unbuffered serum-free DMEM (Basal DMEM, Agilent) supplemented with pyruvate (1mM), glutamine (2mM), and glucose (10mM) for 1 hour at 37°C and at ambient CO₂ (Rademaker et al., 2018). After equilibration, the assay was performed in triplicate for each condition. Oxygen consumption rate (OCR) and pH were measured by the flux analyzer at basal state and after oligomycin (10µM), FCCP (2µM) and Rotenone (5µM) & Antimycin A (5µM). The experiment was repeated for 9 biological replicates.

Results were normalized to proteins concentration obtain after 0.5 N NaOH extraction and Pierce dosage. Data was analyzed with Paired t test if data passed normality tests (D'Agostino & Pearson normality test, Shapiro-Wilk normality test and Kolmogorov-Smirnov test) or with Wilcoxon test if the data does not assume the Gaussian distribution.

5.4.3.RT-qPCR: Pro-inflammatory gene expression

At 80% confluency, cells were treated with different concentrations of NDS27 (0, 7, 14, 21 and 35 μ M). After 2 hours of treatment, the medium was changed with pro-inflammatory medium for 24 hours (TNF α 1 ng/mL and IL-1 β 0.1 ng/mL). Cells were detached and RNA extraction, cDNA retro-transcription and qPCR were performed as described in the part 3. Fold change is related to cells without NDS27 treatment. This experiment was performed for 6 biological replicates for the concentrations 0, 7 and 14 μ M and on 5 biological replicates for concentrations 21 and 35 μ M.

5.4.4.Cell Suspension

Confluent mdMSCs are detached with trypsin, harvested in PBS and centrifuged (10', 230g at RT). Supernatant was discarded, cells were washed with HBSS and recentrifuged (10', 230g at RT). This step was repeated and cells were counted, divided into a number equivalent to different experimental conditions and treated for 10 minutes with the different experimental molecules (NDS27 and HB β CD). Cells were then recentrifuged for the third time (10', 230g at RT). Supernatant was discarded and cells were resuspended with CryoStor[®] CS-5 (Stemcell technologies) (1mL for 10 000 000 cells), placed into a Coolcell[®] at -80°C for few days before to be stored into liquid nitrogen.

5.5. Results

5.5.1.Effects of pro-inflammatory media on mdMSCs mitochondria

As we have shown that curcumin is partially localized into mitochondria of mdMSCs (Colin et al., 2021) and could thus potentially affect this organelle, it is interesting to explore possible effect of curcumin on mitochondrial functions in the pro-inflammatory context of OA. We have thus first assessed the effect of pro-inflammatory medium on mdMSCs' mitochondria. Mitochondrial respiration was measured with 2 different types of respirometry analyses. First, the electron flow through complexes I and II was assessed with a high resolution respirometry called Oroboros. However, cells need to be detached before analysis, possibly inducing a bias. Results presented in the figures 24 A, B and C show that cells treated with TNF α and IL-1 β have a decrease of the electron flow through complexes I and II (respectively measured after cytochrome C, succinate and rotenone).

Flux analyzer was also used to characterize the mitochondrial respiration. This automated equipment allows to work with adherent cells but offers less adaptability than Oroboros. Mito Stress profile showed that maximal OCR was significantly decreased for cells treated with pro-inflammatory media compared to non-treated cells (figures 24 D and E).




Figure 24: Effects of TNF α and IL-1 β on mitochondrial respiration of mdMSCs. A, B, C) Flux control ratio (FCR) obtained with high resolution respirometry (Oroboros) and after adding cytochrome C, succinate and rotenone. n=10 D) Representative profile acquired with flux analyzer (Seahorse) of one biological replicate (assayed in technical duplicates). E) Difference in the maximal oxygen consumption rate (OCR) between non treated cells and cells treated with TNF α and IL-1 β for 24 hours. n=9

The results obtained with these 2 techniques allowed to measure the effect of pro-inflammatory cytokines on mitochondrial respiration and converge toward a significantly decreased respiration.

5.5.2. Influence of NDS27 priming on adherent mdMSCs in pro-inflammatory media

After 2 hours of priming with NDS27, cells were cultured with TNF α and IL-1 β and the expression of genes related to inflammation was assessed by RT-qPCR. Results were compared to cells not primed with NDS27 to study the potential protection conferred by NDS27 against inflammatory stress (figure 25).




Figure 25: Effect of a 2 hour-pretreatment with NDS27 on pro-inflammatory gene expression (IL-8, COX 2 and IL-6). Different concentrations of NDS27 were tested. Results are related to cells not primed with NDS27 but also treated with $TNF\alpha$ and IL- 1β . Results were obtained for 6 biological replicates for NDS27 concentrations 7 and 14 μM and for 5 biological replicates for the highest concentrations.

Whatever the concentration of NDS27 used for the priming, no significant protection conferred by pre-treatment was measured. However, we noticed that biological replicates show an important variability suggesting that some donors could be more sensitive to NDS27 than others.

The absence of protection conferred by NDS27 in pro-inflammatory environment must be interpreted together with the low internalization of curcumin (around 2%) demonstrated in the part 5.2.

Therefore, reflections were carried out with all partners of the project to increase the internalization of NDS27. A protocol respecting constraints of the industrial partner has been proposed to improve the internalization of NDS27 and consists of priming non adherent mdMSCs.

5.5.3. Cell suspension

As mentioned above, priming of cells was performed on cells in suspension according to a protocol optimizing the NDS27 internalization (results not shown) and that respects the production constraints of the future cell therapy product by the industrial partner. This new protocol includes a cryopreservation step to work in the same condition than the future cell therapy product.

First, cells were counted just after thawing to evaluate if the priming mix with cryopreservation process leads to cell loss. Differences in cell number before cryopreservation and after thawing (figure 26A) were not significantly affected by priming conditions. This process leads to 40% reduction in the number of cells compared to the number of cells before cryopreservation.




Figure 26: Treatment of mdMSCs suspension with NDS27 and banking of this product by cryopreservation. A) Immediately after thawing, mdMSCs were counted and compared to the number of cells before freezing. The difference between these 2 counts is expressed as a percentage represented on the graph. n=6 B) 24 hours after thawing and seeding in normal medium or in pro-inflammatory medium, cells were detached and a trypan blue cell counting was performed to define the percentage of mortality. n=4 C) Cells were seeded into Seahorse plate after thawing in pro-inflammatory medium for 24 hours. Respiratory analyses were then performed by Flux analyzer with a Mito Stress profile.

Then, cells were seeded in normal culture medium or in pro-inflammatory medium (to mimic the pro-inflammatory environment of joint suffering from OA and treated with cell therapy product). 24 hours post seeding, cells were detached and counted. A trypan blue counting was performed to determine the percentage of cell mortality (figure 26B) that was not significantly different between conditions.

Finally, as NDS27 is localized in mitochondria, one hypothesis was that NDS27 could be able to restore the mitochondrial function impacted by inflammation. Mitochondrial respiration was then studied with Oroboros (not shown) and Seahorse (figure 26C) and showed similar results: mitochondrial respiration

of the cellular product and 24 hours post seeding is residual as suggested by the unresponsive oxygen consumption rate to different mitochondrial substrates and inhibitors. Priming with NDS27 (7 or 14 μ M) could not restore this loss of respiratory function.

5.6. Discussion

The final part of this thesis has evaluated the potential of an innovant cell therapy product: mdMSCs pretreated with NDS27, a hydrosoluble form of curcumin. The first half of this section was published and showed that:

- NDS27 is internalized into mdMSCs without solvent requirement
- NDS27 is localized into mitochondria, at least partly
- Mesenchymal properties of mdMSCs treated with NDS27 were not altered in these priming conditions

Then, as mitochondria was a targeted organelle by NDS27, we have assessed mitochondrial respiration in pro-inflammatory media with the perspective to develop a new readout to measure the effect of NDS27. Incubation for 24 hours with TNF α and IL-1 β leads to decreased mitochondrial respiration by affecting the electron flow through complexes I and II of mitochondrial chain. This effect was previously documented by other teams and several explanations were proposed for this mitochondrial respiration impairment:

- TNF α decreases activities of complexes I and II (Lkhagva et al., 2018) probably explained by a decrease of NAD⁺/NADH ratio (Hahn et al., 2014)
- TNF α increases ROS production (Lkhagva et al., 2018)
- IL-1 β decreases maximal respiratory capacity (Hahn et al., 2014)

The therapeutic potential of this product cultured with TNF α and IL-1 β was evaluated by studying the pro-inflammatory gene expression. Priming with NDS27 did not allow to decrease the induction of IL-6, COX2 and IL-8 expression in this context. However, the individual sensibility of donors should be studied if an allogenic therapy was considered in the future as well as antioxidant properties of this product.

The absence of protection conferred by the priming of NDS27 with this inflammatory model could be explained by the protocol used for this step and allowing only 2% of curcumin internalization into mdMSCs. A new method of priming was elaborated to improve the NDS27 internalization and to fit to GMP protocols required by the industrial partner constraints. Unfortunately, the several steps required to prepare this cryopreserved product leads to high cytotoxicity as shown by the loss of cells during this process, the high rate of mortality and the residual mitochondrial respiration 24 hours post-seeding. Moll

et al., suggest that thawed MSCs need to recover in culture for 24-72 hours before cell therapy to avoid the unresponsiveness state after thawing (Moll et al., 2016). Antebi et al., showed that a period of 24 hours post thawed is sufficient to allow cryopreserved MSCs to recover their stem cell functions (Antebi et al., 2019). As thawing is described to alter the actin cytoskeletal of MSCs (Chinnadurai et al., 2014), an organelle implicated in several fundamental functions (like motility, adhesion, interaction with environment,...), its damage caused especially cytotoxicity (X. Liu et al., 2019). Industrial partner needs to consider these results to evaluate the beneficial impact to let mdMSCs recover at least 24 hours in culture before using this cellular product in therapy.

Perspectives are now to study the effect of this cellular product because apoptotic MSCs were already used in pre-clinical lung injury with positive effects on inflammatory. Although the mechanism is not known, a proposed hypothesis is that apoptotic MSCs can damp the immune response (D. J. Weiss et al., 2019). Different EV are released from apoptotic MSCs and lead to modulate the immune response, favorably or not (Caruso & Poon, 2018). It is therefore essential to assess the functional effect of developed cell therapy product and if it has shown protective effects on cartilage explants cultured in the *in vitro* osteoarthritis model. It would be very interesting to study the paracrine function of these apoptotic mdMSCs. Finally, the potentiation of this property by the presence of NDS27 itself or by its degradation products should be assessed, including the potential activity of this product on oxidative stress.

5.7. Conclusions

This applied part concerned the development of an innovative therapeutic product based on mdMSCs primed with a hydrosoluble form of curcumin called NDS27. We showed that this priming allows to internalize NDS27 into these cells. However, no positive effect of this treatment could be demonstrated in this pro-inflammatory environment on IL-6, COX2 and IL-8 genes expression. Industrial partner needs to optimize the conditions of therapeutic using, especially the time of recovering after thawing. Then, potential therapeutic effect and fate of NDS27 in this product will be studied.

7.2. Donors' informations

Age at harvesting	Sex	Donor for	Reason of euthanized
5	Female	mdMSCs	
6	Female	mdMSCs	
10	Female	mdMSCs	
12	Female	mdMSCs	
13	Female	mdMSCs	
14	Female	mdMSCs	
16	Female	mdMSCs	
22	Female	mdMSCs	
10	Male	mdMSCs	
22	Male	mdMSCs	
27	Male	mdMSCs	
21	Female	Cartilage – SILAC experiment	Colic
3	Male	Cartilage – SILAC experiment	Joint wound
14	Male	Cartilage – SILAC experiment	Laminitis
7	Male	Cartilage – Functional experiments	Colic
9	Male	Cartilage – Functional experiments	Tetanus
12	Male	Cartilage – Functional experiments	Colic
14	Male	Cartilage – Functional experiments	Colic
16	Male	Cartilage – Functional experiments	Colic
17	Male	Cartilage – Functional experiments	Colic

Bibliography

8. Bibliography

- Abbott, J., & Holtzer, H. (1966). The loss of phenotypic traits by differentiated cells. 3. The reversible behavior of chondrocytes in primary cultures. *The Journal of Cell Biology*, 28(3), 473–487. <https://doi.org/10.1083/JCB.28.3.473>
- Abdollahi, E., Momtazi, A. A., Johnston, T. P., & Sahebkar, A. (2018). Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: A nature-made jack-of-all-trades? *Journal of Cellular Physiology*, 233(2), 830–848. <https://doi.org/10.1002/jcp.25778>
- AFMPS. (2018). Utilisation de produits à base de cellules souches en médecine vétérinaire | AFMPS. Retrieved May 5, 2021, from https://www.afmps.be/fr/news/utilisation_de_produits_a_base_de_cellules_souches_en_medecine_veterinaire
- Alcaraz, M. J., Compañ, A., & Guillén, M. I. (2019, December 31). Extracellular Vesicles from Mesenchymal Stem Cells as Novel Treatments for Musculoskeletal Diseases. *Cells*. NLM (Medline). <https://doi.org/10.3390/cells9010098>
- Almalki, S. G., & Agrawal, D. K. (2016, July 1). Key transcription factors in the differentiation of mesenchymal stem cells. *Differentiation*. Elsevier Ltd. <https://doi.org/10.1016/j.diff.2016.02.005>
- Alsalameh, S., Amin, R., Gemba, T., & Lotz, M. (2004). Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. *Arthritis and Rheumatism*, 50(5), 1522–1532. <https://doi.org/10.1002/ART.20269>
- Alves, C. R., Perosa Fernandes, R., Fonseca-Santos, B., Damiani Victorelli, F., & Chorilli, M. (2019). A Critical Review of the Properties and Analytical Methods for the Determination of Curcumin in Biological and Pharmaceutical Matrices. *Critical Reviews in Analytical Chemistry*, 49(2), 138–149. <https://doi.org/10.1080/10408347.2018.1489216>
- Anderson, J. R., Phelan, M. M., Foddy, L., Clegg, P. D., & Peffers, M. J. (2020). Ex Vivo Equine Cartilage Explant Osteoarthritis Model: A Metabolomics and Proteomics Study. *Journal of Proteome Research*, 19(9), 3652–3667. <https://doi.org/10.1021/acs.jproteome.0c00143>
- Antebi, B., Asher, A. M., Rodriguez, L. A., Moore, R. K., Mohammadipoor, A., & Cancio, L. C. (2019). Cryopreserved mesenchymal stem cells regain functional potency following a 24-h acclimation period. *Journal of Translational Medicine*, 17(1). <https://doi.org/10.1186/s12967-019-2038-5>
- Armiento, A. R., Alini, M., & Stoddart, M. J. (2019, June 1). Articular fibrocartilage - Why does hyaline cartilage fail to repair? *Advanced Drug Delivery Reviews*. Elsevier B.V. <https://doi.org/10.1016/j.addr.2018.12.015>
- Arrigoni, C., Arrigo, D. D., Rossella, V., Candrian, C., Albertini, V., & Moretti, M. (2020). Umbilical Cord MSCs and Their Secretome in the Therapy of Arthritic Diseases: A Research and Industrial Perspective, 1–20. <https://doi.org/10.3390/cells9061343>
- Azambuja da Silva, A., Pinto da Rosa, P., Mackmill, L., & Roll, V. (2021). An assessment of the effectiveness of hyaluronic acid and polyacrylamide hydrogel in horses with osteoarthritis: Systematic review and network meta-analysis. *Research in Veterinary Science*, 134, 42–50. <https://doi.org/10.1016/J.RVSC.2020.11.013>
- Bapat, S., Hubbard, D., Munjal, A., Hunter, M., & Fulzele, S. (2018). Pros and cons of mouse models for studying osteoarthritis. *Clinical and Translational Medicine*, 7(1), 36. <https://doi.org/10.1186/s40169-018-0215-4>
- Bara, J. J., McCarthy, H. E., Humphrey, E., Johnson, W. E. B., & Roberts, S. (2014). Bone marrow-derived mesenchymal stem cells become antiangiogenic when chondrogenically or osteogenically differentiated: Implications for bone and cartilage tissue engineering. *Tissue Engineering - Part A*, 20(1–2), 147–159. <https://doi.org/10.1089/ten.tea.2013.0196>
- Baraniak, P., & McDevitt, T. (2010). Stem cell paracrine actions and tissue regeneration. *Regenerative Medicine*, 5(1), 121–143. <https://doi.org/10.2217/RME.09.74>
- Bari, S., Kwee Hong Seah, K., Poon, Z., Man Sze Cheung, A., Fan, X., Ong, S.-Y., ... Ying Khee Hwang, W. (2015). Expansion and Homing of Umbilical Cord Blood Hematopoietic Stem and Progenitor Cells for Clinical Transplantation. <https://doi.org/10.1016/j.bbmt.2014.12.022>
- Barreto, G., Senturk, B., Colombo, L., Brück, O., Neidenbach, P., Salzmann, G., ... Rottmar, M. (2020). Lumican is upregulated in osteoarthritis and contributes to TLR4-induced pro-inflammatory activation of cartilage degradation and macrophage polarization. *Osteoarthritis and Cartilage*, 28(1), 92–101. <https://doi.org/10.1016/j.joca.2019.10.011>
- Barzegar, A., & Moosavi-Movahedi, A. A. (2011). Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin. *PLoS One*, 6(10), e26012. <https://doi.org/10.1371/journal.pone.0026012>
- Belluzzi, E., Stocco, E., Pozzuoli, A., Granzotto, M., Porzionato, A., Vettor, R., ... MacChi, V. (2019). Contribution of Infrapatellar Fat Pad and Synovial Membrane to Knee Osteoarthritis Pain. *BioMed Research International*. Hindawi Limited. <https://doi.org/10.1155/2019/6390182>
- Ben-Aderet, L., Merquiol, E., Fahham, D., Kumar, A., Reich, E., Ben-Nun, Y., ... Dvir-Ginzberg, M. (2015). Detecting cathepsin activity in human osteoarthritis via activity-based probes. *Arthritis Research and*

- Therapy*, 17(1), 69. <https://doi.org/10.1186/s13075-015-0586-5>
- Benya, P. D., Padilla, S. R., & Nimni, M. E. (1978). Independent regulation of collagen types by chondrocytes during the loss of differentiated function in culture. *Cell*, 15(4), 1313–1321. [https://doi.org/10.1016/0092-8674\(78\)90056-9](https://doi.org/10.1016/0092-8674(78)90056-9)
- Berenbaum, F. (2013). Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). *Osteoarthritis and Cartilage*, 21(1), 16–21. <https://doi.org/10.1016/J.JOCA.2012.11.012>
- Bertoni, L., Jacquet-Guibon, S., Branly, T., Legendre, F., Desancé, M., Mespoulhes, C., ... Audigié, F. (2020). An experimentally induced osteoarthritis model in horses performed on both metacarpophalangeal and metatarsophalangeal joints: technical, clinical, imaging, biochemical, macroscopic and microscopic characterization. *PLoS ONE*, 15(6), 1–22. <https://doi.org/10.1371/journal.pone.0235251>
- Bertuglia, A., Pagliara, E., Grego, E., Ricci, A., & Brkljaca-Bottegaro, N. (2016). Pro-inflammatory cytokines and structural biomarkers are effective to categorize osteoarthritis phenotype and progression in Standardbred racehorses over five years of racing career. *BMC Veterinary Research*, 12(1), 1–15. <https://doi.org/10.1186/s12917-016-0873-7>
- Brama, P., Tekoppele, J., Bank, R., Karsenberg, D., Barneveld, A., & van Weeren, P. (2000). Topographical mapping of biochemical properties of articular cartilage in the equine fetlock joint. *Equine Veterinary Journal*, 32(1), 19–26. <https://doi.org/10.2746/042516400777612062>
- Brandi, J., Manfredi, M., Speziali, G., Gosetti, F., Marengo, E., & Cecconi, D. (2018). Proteomic approaches to decipher cancer cell secretome. *Seminars in Cell and Developmental Biology*, 78, 93–101. <https://doi.org/10.1016/j.semcdb.2017.06.030>
- Buckwalter, J. (2002). Articular cartilage injuries. *Clinical Orthopaedics and Related Research*, (402), 21–37. <https://doi.org/10.1097/00003086-200209000-00004>
- Bundgaard, L., Stensballe, A., Elbæk, K. J., & Berg, L. C. (2020). Mass spectrometric analysis of the in vitro secretome from equine bone marrow-derived mesenchymal stromal cells to assess the effect of chondrogenic differentiation on response to interleukin-1 β treatment. *Stem Cell Research & Therapy*, 11(1), 187. <https://doi.org/10.1186/s13287-020-01706-7>
- Bussche, L., & Van de Walle, G. R. (2014). Peripheral Blood-Derived Mesenchymal Stromal Cells Promote Angiogenesis via Paracrine Stimulation of Vascular Endothelial Growth Factor Secretion in the Equine Model. *STEM CELLS Translational Medicine*, 3(12), 1514–1525. <https://doi.org/10.5966/sctm.2014-0138>
- Calich, A. L. G., Domiciano, D. S., & Fuller, R. (2010, May). Osteoarthritis: Can anti-cytokine therapy play a role in treatment? *Clinical Rheumatology*. Clin Rheumatol. <https://doi.org/10.1007/s10067-009-1352-3>
- Caruso, S., & Poon, I. K. H. (2018, June 28). Apoptotic cell-derived extracellular vesicles: More than just debris. *Frontiers in Immunology*. Frontiers Media S.A. <https://doi.org/10.3389/fimmu.2018.01486>
- Cequier, A., Sanz, C., Rodellar, C., & Barrachina, L. (2021, April 1). The usefulness of mesenchymal stem cells beyond the musculoskeletal system in horses. *Animals*. MDPI AG. <https://doi.org/10.3390/ani11040931>
- Ceusters, J., Lejeune, J. P., Sandersen, C., Niesten, A., Lagneaux, L., & Serteyn, D. (2017). From skeletal muscle to stem cells: An innovative and minimally-invasive process for multiple species. *Scientific Reports*. <https://doi.org/10.1038/s41598-017-00803-7>
- Charlier, E., Deroyer, C., Ciregia, F., Malaise, O., Neuville, S., Plener, Z., ... de Seny, D. (2019). Chondrocyte dedifferentiation and osteoarthritis (OA). *Biochemical Pharmacology*, 165(February), 49–65. <https://doi.org/10.1016/j.bcp.2019.02.036>
- Charlier, E., Relic, B., Deroyer, C., Malaise, O., Neuville, S., Collée, J., ... De Seny, D. (2016, December 20). Insights on molecular mechanisms of chondrocytes death in osteoarthritis. *International Journal of Molecular Sciences*. MDPI AG. <https://doi.org/10.3390/ijms17122146>
- Charni, N., Juillet, F., & Garnero, P. (2005). Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. *Arthritis and Rheumatism*, 52(4), 1081–1090. <https://doi.org/10.1002/ART.20930>
- Chen, S., Fu, P., Wu, H., & Pei, M. (2017, October 1). Meniscus, articular cartilage and nucleus pulposus: a comparative review of cartilage-like tissues in anatomy, development and function. *Cell and Tissue Research*. Springer Verlag. <https://doi.org/10.1007/s00441-017-2613-0>
- Chiabotto, G., Pasquino, C., Camussi, G., & Bruno, S. (2020, December 8). Molecular Pathways Modulated by Mesenchymal Stromal Cells and Their Extracellular Vesicles in Experimental Models of Liver Fibrosis. *Frontiers in Cell and Developmental Biology*. Frontiers Media S.A. <https://doi.org/10.3389/fcell.2020.594794>
- Chinnadurai, R., Garcia, M. A., Sakurai, Y., Lam, W. A., Kirk, A. D., Galipeau, J., & Copland, I. B. (2014). Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo. *Stem Cell Reports*, 3(1), 60–72. <https://doi.org/10.1016/j.stemcr.2014.05.003>
- Clutterbuck, A. L., Smith, J. R., Allaway, D., Harris, P., Liddell, S., & Mobasher, A. (2011). High throughput proteomic analysis of the secretome in an explant model of articular cartilage inflammation. *Journal of Proteomics*, 74(5), 704–715. <https://doi.org/10.1016/j.jprot.2011.02.017>

- Cohen, N., Foster, R., & Mow, V. (1998). Composition and dynamics of articular cartilage: structure, function, and maintaining healthy state. *The Journal of Orthopaedic and Sports Physical Therapy*, 28(4), 203–215. <https://doi.org/10.2519/JOSPT.1998.28.4.203>
- Colin, M., Dechêne, L., Ceusters, J., Niesten, A., Demazy, C., Lagneaux, L., ... Serteyn, D. (2021). Priming of mesenchymal stem cells with a hydrosoluble form of curcumin allows keeping their mesenchymal properties for cell-based therapy development. *Journal of Cellular and Molecular Medicine*, 00, jemm.16403. <https://doi.org/10.1111/jcmm.16403>
- Cook, A. E., Cook, J. L., & Stoker, A. M. (2018). Metabolic Responses of Meniscus to IL-1 β . *Journal of Knee Surgery*, 31(9), 834–840. <https://doi.org/10.1055/s-0037-1615821>
- Coon, J. J., Syka, J. E. P., Shabanowitz, J., & Hunt, D. F. (2005, May 30). Tandem mass spectrometry for peptide and protein sequence analysis. *BioTechniques*. Eaton Publishing Company. <https://doi.org/10.2144/05384TE01>
- Cope, P. J., Ourradi, K., Li, Y., & Sharif, M. (2019). Models of osteoarthritis: the good, the bad and the promising. *Osteoarthritis and Cartilage*, 27(2), 230–239. <https://doi.org/10.1016/j.joca.2018.09.016>
- D'Arrigo, D., Roffi, A., Cucchiaroni, M., Moretti, M., Candrian, C., & Filardo, G. (2019). Secretome and Extracellular Vesicles as New Biological Therapies for Knee Osteoarthritis: A Systematic Review. *Journal of Clinical Medicine*, 8(11), 1867. <https://doi.org/10.3390/jcm8111867>
- de Araújo Farias, V., Carrillo-Gálvez, A. B., Martín, F., & Anderson, P. (2018). TGF- β and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer. *Cytokine and Growth Factor Reviews*, 43(June), 25–37. <https://doi.org/10.1016/j.cytogfr.2018.06.002>
- De Becker, A., & Van Riet, I. (2016). Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? *World Journal of Stem Cells*, 8(3), 73–87. <https://doi.org/10.4252/WJSC.V8.I3.73>
- de Faria, C. A., Zanette, D. L., Silva, W. A., & Ribeiro-Paes, J. T. (2019, February 1). PAI-1 inhibition by simvastatin as a positive adjuvant in cell therapy. *Molecular Biology Reports*. Springer Netherlands. <https://doi.org/10.1007/s11033-018-4562-4>
- Deguchi, T., Hashizume, H., Nakajima, M., Teraguchi, M., Akune, T., Yamada, H., ... Ikegawa, S. (2019). A population-based study identifies an association of THBS2 with intervertebral disc degeneration. *Osteoarthritis and Cartilage*, 27, 1501–1507. <https://doi.org/10.1016/j.joca.2019.06.001>
- Derochette, S., Mouithys-Mickalad, A., Franck, T., Collienne, S., Ceusters, J., Deby-Dupont, G., ... Serteyn, D. (2014). NDS27 combines the effect of curcumin lysinate and hydroxypropyl- β -cyclodextrin to inhibit equine PKC δ and NADPH oxidase involved in the oxidative burst of neutrophils. *FEBS Open Bio*. <https://doi.org/10.1016/j.fob.2014.11.004>
- Dhillon, N., Aggarwal, B., Newman, R., Wolff, R., Kunnumakkara, A., Abbruzzese, J., ... Kurzrock, R. (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, 14(14), 4491–4499. <https://doi.org/10.1158/1078-0432.CCR-08-0024>
- Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D. S., ... Horwitz, E. M. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*, 8(4), 315–317. <https://doi.org/10.1080/14653240600855905>
- Driscoll, J., & Patel, T. (2019). The mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease. *Journal of Gastroenterology*, 54(9), 763–773. <https://doi.org/10.1007/s00535-019-01599-1>
- Eleuteri, S., & Fierabracci, A. (2019). Insights into the secretome of mesenchymal stem cells and its potential applications. *International Journal of Molecular Sciences*, 20(18). <https://doi.org/10.3390/ijms20184597>
- Eyre, D. (2002). Collagen of articular cartilage. *Arthritis Research*, 4(1), 30–35. <https://doi.org/10.1186/AR380>
- Fahy, N., Alini, M., & Stoddart, M. J. (2018). Mechanical stimulation of mesenchymal stem cells: Implications for cartilage tissue engineering. *Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society*, 36(1), 52–63. <https://doi.org/10.1002/JOR.23670>
- Ferreira, J. R., Teixeira, G. Q., Santos, S. G., Barbosa, M. A., Almeida-Porada, G., & Gonçalves, R. M. (2018). Mesenchymal stromal cell secretome: Influencing therapeutic potential by cellular pre-conditioning. *Frontiers in Immunology*, 9(December), 1–17. <https://doi.org/10.3389/fimmu.2018.02837>
- Franck, T., Aldib, I., Zouaoui Boudjeltia, K., Furtmüller, P. G., Obinger, C., Neven, P., ... Serteyn, D. (2019). The soluble curcumin derivative NDS27 inhibits superoxide anion production by neutrophils and acts as substrate and reversible inhibitor of myeloperoxidase. *Chemico-Biological Interactions*, 297, 34–43. <https://doi.org/10.1016/j.cbi.2018.10.008>
- Friedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970). The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell and Tissue Kinetics*, 3(4), 393–403. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/5523063>
- Gao, Y., Liu, S., Huang, J., Guo, W., Chen, J., Zhang, L., ... Guo, Q. (2014). The ECM-cell interaction of cartilage extracellular matrix on chondrocytes. *BioMed Research International*. Hindawi Publishing Corporation.

- <https://doi.org/10.1155/2014/648459>
- Gilbert, S. J., Singhrao, S. K., Khan, I. M., Gonzalez, L. G., Thomson, B. M., Burdon, D., ... Archer, C. W. (2009). Enhanced tissue integration during cartilage repair in vitro can be achieved by inhibiting chondrocyte death at the wound edge. *Tissue Engineering - Part A*, *15*(7), 1739–1749. <https://doi.org/10.1089/ten.tea.2008.0361>
- Gnaiger, E., Kuznetsov, A. V., Schneeberger, S., Seiler, R., Brandacher, G., Steurer, W., & Margreiter, R. (2000). Mitochondria in the Cold. In *Life in the Cold* (pp. 431–442). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-662-04162-8_45
- Goodrich, L. R., & Nixon, A. J. (2006). Medical treatment of osteoarthritis in the horse - A review. *Veterinary Journal*, *171*(1), 51–69. <https://doi.org/10.1016/j.tvjl.2004.07.008>
- Gorabi, A. M., Kiaie, N., Hajighasemi, S., Jamialahmadi, T., Majeed, M., & Sahebkar, A. (2019). The Effect of Curcumin on the Differentiation of Mesenchymal Stem Cells into Mesodermal Lineage. *Molecules*, *24*(4029). <https://doi.org/10.3390/molecules24224029>
- Grafe, I., Alexander, S., Peterson, J. R., Snider, T. N., Levi, B., Lee, B., & Mishina, Y. (2018). Differentiation, 1–49.
- Griffith, T., Kazama, H., VanOosten, R., Earle, J., Herndon, J., Green, D., & Ferguson, T. (2007). Apoptotic cells induce tolerance by generating helpless CD8⁺ T cells that produce TRAIL. *Journal of Immunology (Baltimore, Md. : 1950)*, *178*(5), 2679–2687. <https://doi.org/10.4049/JIMMUNOL.178.5.2679>
- Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013). Therapeutic roles of curcumin: Lessons learned from clinical trials. *AAPS Journal*, *15*(1), 195–218. <https://doi.org/10.1208/s12248-012-9432-8>
- Hahn, W. S., Kuzmicic, J., Burrill, J. S., Donoghue, M. A., Foncea, R., Jensen, M. D., ... Bernlohr, D. A. (2014). Proinflammatory cytokines differentially regulate adipocyte mitochondrial metabolism, oxidative stress, and dynamics. *American Journal of Physiology - Endocrinology and Metabolism*, *306*(9), 1033–1045. <https://doi.org/10.1152/ajpendo.00422.2013>
- Hall, A. C. (2019, August 1). The Role of Chondrocyte Morphology and Volume in Controlling Phenotype—Implications for Osteoarthritis, Cartilage Repair, and Cartilage Engineering. *Current Rheumatology Reports*. Current Medicine Group LLC 1. <https://doi.org/10.1007/s11926-019-0837-6>
- Haltmayer, E., Ribitsch, I., Gabner, S., Rosser, J., Gueltekin, S., Peham, J., ... Jenner, F. (2019). Co-culture of osteochondral explants and synovial membrane as in vitro model for osteoarthritis. *PLoS ONE*, *14*(4), 1–19. <https://doi.org/10.1371/journal.pone.0214709>
- Hammond, D. E., Kumar, J. D., Raymond, L., Simpson, D. M., Beynon, R. J., Dockray, G. J., & Varro, A. (2018). Stable isotope dynamic labeling of secretomes (SIDLs) identifies authentic secretory proteins released by cancer and stromal cells. *Molecular and Cellular Proteomics*, *17*(9), 1837–1849. <https://doi.org/10.1074/mcp.TIR117.000516>
- Han, B., Li, Q., Wang, C., Patel, P., Adams, S. M., Doyran, B., ... Han, L. (2019). Decorin Regulates the Aggrecan Network Integrity and Biomechanical Functions of Cartilage Extracellular Matrix. *ACS Nano*, *13*(10), 11320–11333. <https://doi.org/10.1021/acsnano.9b04477>
- Hankenson, K., & Bornstein, P. (2002). The secreted protein thrombospondin 2 is an autocrine inhibitor of marrow stromal cell proliferation. *Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research*, *17*(3), 415–425. <https://doi.org/10.1359/JBMR.2002.17.3.415>
- Harasymowicz, N. S., Azfer, A., Burnett, R., Simpson, H., & Salter, D. M. (2021). Chondrocytes from osteoarthritic cartilage of obese patients show altered adiponectin receptors expression and response to adiponectin. *Journal of Orthopaedic Research*. <https://doi.org/10.1002/jor.24993>
- Harman, R. M., He, M. K., Zhang, S., & Van de Walle, G. R. (2018). Plasminogen activator inhibitor-1 and tenascin-C secreted by equine mesenchymal stromal cells stimulate dermal fibroblast migration in vitro and contribute to wound healing in vivo. *Cytotherapy*, *20*(8), 1061–1076. <https://doi.org/10.1016/j.jcyt.2018.06.005>
- Harman, R. M., Marx, C., & Van de Walle, G. R. (2021, March 19). Translational Animal Models Provide Insight Into Mesenchymal Stromal Cell (MSC) Secretome Therapy. *Frontiers in Cell and Developmental Biology*. Frontiers Media S.A. <https://doi.org/10.3389/fcell.2021.654885>
- Harrell, C., Fellabaum, C., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019). Molecular Mechanisms Responsible for Therapeutic Potential of Mesenchymal Stem Cell-Derived Secretome. *Cells*, *8*(5), 467. <https://doi.org/10.3390/cells8050467>
- Harrell, C., Markovic, B. S., Fellabaum, C., Arsenijevic, A., & Volarevic, V. (2019). Mesenchymal stem cell-based therapy of osteoarthritis: Current knowledge and future perspectives. *Biomedicine and Pharmacotherapy*, *109*(June 2018), 2318–2326. <https://doi.org/10.1016/j.biopha.2018.11.099>
- Harting, M., Srivastava, A., Zhaorigetu, S., Bair, H., Prabhakara, K., Toledano Furman, N., ... Olson, S. (2018). Inflammation-Stimulated Mesenchymal Stromal Cell-Derived Extracellular Vesicles Attenuate Inflammation. *Stem Cells (Dayton, Ohio)*, *36*(1), 79–90. <https://doi.org/10.1002/STEM.2730>
- Hartog, A., Hougee, S., Faber, J., Sanders, A., Zuurman, C., Smit, H. F., ... Garssen, J. (2008). The

- multicomponent phytopharmaceutical SKI306X inhibits in vitro cartilage degradation and the production of inflammatory mediators. *Phytomedicine*, 15(5), 313–320. <https://doi.org/10.1016/j.phymed.2007.09.005>
- Haseeb, A., & Haqqi, T. M. (2013, March). Immunopathogenesis of osteoarthritis. *Clinical Immunology*. Clin Immunol. <https://doi.org/10.1016/j.clim.2012.12.011>
- Hass, R., Kasper, C., Böhm, S., & Jacobs, R. (2011). Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. *Cell Communication and Signaling: CCS*, 9. <https://doi.org/10.1186/1478-811X-9-12>
- He, Y., Li, Z., Alexander, P. G., Ocasio-Nieves, B. D., Yocum, L., Lin, H., & Tuan, R. S. (2020). Pathogenesis of Osteoarthritis: Risk Factors, Regulatory Pathways in Chondrocytes, and Experimental Models. *Biology*, 9(8), 194. <https://doi.org/10.3390/biology9080194>
- Herencia, C., Martínez-Moreno, J. M., Herrera, C., Corrales, F., Santiago-Mora, R., Espejo, I., ... Muñoz-Castañeda, J. R. (2012). Nuclear translocation of β -catenin during mesenchymal stem cells differentiation into hepatocytes is associated with a tumoral phenotype. *PLoS ONE*, 7(4). <https://doi.org/10.1371/journal.pone.0034656>
- Huang, X.-P., Sun, Z., Miyagi, Y., McDonald Kinkaid, H., Zhang, L., Weisel, R., & Li, R.-K. (2010). Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. *Circulation*, 122(23), 2419–2429. <https://doi.org/10.1161/CIRCULATIONAHA.110.955971>
- Huh, J. E., Baek, Y. H., Ryu, S. R., Lee, J. D., Choi, D. Y., & Park, D. S. (2009). Efficacy and mechanism of action of KHBj-9B, a new herbal medicine, and its major compound triterpenoids in human cartilage culture and in a rabbit model of collagenase-induced osteoarthritis. *International Immunopharmacology*, 9(2), 230–240. <https://doi.org/10.1016/j.intimp.2008.11.016>
- Hui, W., Litherland, G. J., Jefferson, M., Barter, M. J., Elias, M. S., Cawston, T. E., ... Young, D. A. (2010). Lithium protects cartilage from cytokine-mediated degradation by reducing collagen-degrading MMP production via inhibition of the p38 mitogen-activated protein kinase pathway. *Rheumatology*, 49(11), 2043–2053. <https://doi.org/10.1093/rheumatology/keq217>
- Hunter, D. J., & Bierma-Zeinstra, S. (2019, April 27). Osteoarthritis. *The Lancet*. Lancet Publishing Group. [https://doi.org/10.1016/S0140-6736\(19\)30417-9](https://doi.org/10.1016/S0140-6736(19)30417-9)
- Jackson, W. M., Nesti, L. J., & Tuan, R. S. (2010). Potential therapeutic applications of muscle-derived mesenchymal stem and progenitor cells. *Expert Opin Biol Ther*, 10(4), 505–517. <https://doi.org/10.1517/14712591003610606>
- Jang, S., Lee, K., & Ju, J. H. (2021). Molecular Sciences Recent Updates of Diagnosis, Pathophysiology, and Treatment on Osteoarthritis of the Knee. <https://doi.org/10.3390/ijms22052619>
- Jeong, S. Y., Kim, D. H., Ha, J., Jin, H. J., Kwon, S. J., Chang, J. W., ... Jeon, H. B. (2013). Thrombospondin-2 secreted by human umbilical cord blood-derived mesenchymal stem cells promotes chondrogenic differentiation. *Stem Cells*, 31(10), 2136–2148. <https://doi.org/10.1002/stem.1471>
- Jiang, Y., Cai, Y., Zhang, W., Yin, Z., Hu, C., Tong, T., ... Ouyang, H. W. (2016). Human Cartilage-Derived Progenitor Cells From Committed Chondrocytes for Efficient Cartilage Repair and Regeneration. *STEM CELLS Translational Medicine*, 5(6), 733–744. <https://doi.org/10.5966/sctm.2015-0192>
- Johnson, C. I., Argyle, D. J., & Clements, D. N. (2016, March 1). In vitro models for the study of osteoarthritis. *Veterinary Journal*. Bailliere Tindall Ltd. <https://doi.org/10.1016/j.tvjl.2015.07.011>
- Joswig, A., Mitchell, A., Cummings, A. J., Levine, G., Gregory, C., Smith, R., & Watts, A. (2017). Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model. *Stem Cell Research & Therapy*, 8(1), 42. <https://doi.org/10.1186/S13287-017-0503-8>
- Judson, R. N., Zhang, R. H., & Rossi, F. M. A. (2013). Tissue-resident mesenchymal stem/progenitor cells in skeletal muscle: Collaborators or saboteurs? *FEBS Journal*, 280(17), 4100–4108. <https://doi.org/10.1111/febs.12370>
- Juneja, S. C., & Veillette, C. (2013). Defects in Tendon, Ligament, and Entesis in Response to Genetic Alterations in Key Proteoglycans and Glycoproteins: A Review. *Arthritis*, 2013, 1–30. <https://doi.org/10.1155/2013/154812>
- Kardos, D., Marschall, B., Simon, M., Hornyák, I., Hinsenkamp, A., Kuten, O., ... Lacza, Z. (2019). Investigation of Cytokine Changes in Osteoarthritic Knee Joint Tissues in Response to Hyperacute Serum Treatment. *Cells*, 8(8). <https://doi.org/10.3390/cells8080824>
- Keller, A., Nesvizhskii, A. I., Kolker, E., & Aebersold, R. (2002). Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. *Analytical Chemistry*, 74(20), 5383–5392. <https://doi.org/10.1021/ac025747h>
- Kern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006). Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue. *STEM CELLS*, 24(5), 1294–1301. <https://doi.org/10.1634/STEMCELLS.2005-0342>

- Kim, N., & Cho, S. G. (2016, February 1). Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications. *International Journal of Hematology*. Springer-Verlag Tokyo. <https://doi.org/10.1007/s12185-015-1918-6>
- Krishnan, Y., & Grodzinsky, A. J. (2018, October 1). Cartilage diseases. *Matrix Biology*. Elsevier B.V. <https://doi.org/10.1016/j.matbio.2018.05.005>
- Kumar, A., Kadamb, A. G., & Kadamb, K. G. (2020, September 1). Mesenchymal or maintenance stem cell & understanding their role in osteoarthritis of the knee joint: A review article. *Archives of Bone and Joint Surgery*. Mashhad University of Medical Sciences. <https://doi.org/10.22038/abjs.2020.42536.2155>
- Kunnumakkara, A. B., Bordoloi, D., Padmavathi, G., Monisha, J., Roy, N. K., Prasad, S., & Aggarwal, B. B. (2017). Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. *British Journal of Pharmacology*, 174(11), 1325–1348. <https://doi.org/10.1111/bph.13621>
- Kupcova Skalnikova, H. (2013). Proteomic techniques for characterisation of mesenchymal stem cell secretome. *Biochimie*, 95(12), 2196–2211. <https://doi.org/10.1016/j.biochi.2013.07.015>
- Kwon, J. H., Kim, M., Bae, Y. K., Kim, G.-H., Choi, S. J., Oh, W., ... Jin, H. J. (2019). Decorin Secreted by Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Induces Macrophage Polarization via CD44 to Repair Hyperoxic Lung Injury. *International Journal of Molecular Sciences*, 20. <https://doi.org/10.3390/ijms20194815>
- Lai, P., Weng, J., Guo, L., Chen, X., & Du, X. (2019). Novel insights into MSC-EVs therapy for immune diseases. *Biomarker Research*, 7(1). <https://doi.org/10.1186/s40364-019-0156-0>
- Lans, C., & Brown, G. (1998). Ethnoveterinary medicines used for ruminants in Trinidad and Tobago. *Preventive Veterinary Medicine*, 35(3), 149–163. [https://doi.org/10.1016/S0167-5877\(98\)00066-X](https://doi.org/10.1016/S0167-5877(98)00066-X)
- Lee, Y.-R., Briggs, M. T., Condina, M. R., Puddy, H., Anderson, P. H., Hoffmann, P., & Kuliwaba, J. S. (2020). Mass Spectrometry Imaging as a Potential Tool to Investigate Human Osteoarthritis at the Tissue Level. *International Journal of Molecular Sciences*, 21(17), 6414. <https://doi.org/10.3390/ijms21176414>
- Lerner, A., Neidhöfer, S., Reuter, S., & Matthias, T. (2018, August 1). MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis. *Best Practice and Research: Clinical Rheumatology*. Bailliere Tindall Ltd. <https://doi.org/10.1016/j.berh.2019.01.006>
- Levato, R., Webb, W., Otto, I., Mensinga, A., Zhang, Y., van Rijen, M., ... Malda, J. (2017). The bio in the ink: cartilage regeneration with bioprintable hydrogels and articular cartilage-derived progenitor cells. *Acta Biomaterialia*, 61, 41–53. <https://doi.org/10.1016/J.ACTBIO.2017.08.005>
- Li, N., & Hua, J. (2017). Interactions between mesenchymal stem cells and the immune system. *Cellular and Molecular Life Sciences*, 74(13), 2345–2360. <https://doi.org/10.1007/s00018-017-2473-5>
- Li, P., Ning, Y., Wang, W., Guo, X., Poulet, B., Wang, X., ... Xu, P. (2020). The integrative analysis of DNA methylation and mRNA expression profiles confirmed the role of selenocompound metabolism pathway in Kashin-Beck disease. *Cell Cycle*, 19(18), 2351–2366. <https://doi.org/10.1080/15384101.2020.1807665>
- Li, Q., Han, B., Wang, C., Tong, W., Wei, Y., Tseng, W., ... Han, L. (2020). Mediation of Cartilage Matrix Degeneration and Fibrillation by Decorin in Post-traumatic Osteoarthritis. *Arthritis & Rheumatology*, 72(8), 1266–1277. <https://doi.org/10.1002/art.41254>
- Li, Y., Wright, G. L., & Peterson, J. M. (2017). C1q/TNF-Related Protein 3 (CTRP3) Function and Regulation. *Compr Physiol*, 7, 863–878. <https://doi.org/10.1002/cphy.c160044>
- Liao, W., Li, Z., Li, T., Zhang, Q., Zhang, H., & Wang, X. (2018). Proteomic analysis of synovial fluid in osteoarthritis using SWATH-mass spectrometry. *Molecular Medicine Reports*, 17(2), 2827–2836. <https://doi.org/10.3892/mmr.2017.8250>
- Lin, Z., Li, Z., Li, E. N., Li, X., Del Duke, C. J., Shen, H., ... Lin, H. (2019). Osteochondral Tissue Chip Derived From iPSCs: Modeling OA Pathologies and Testing Drugs. *Frontiers in Bioengineering and Biotechnology*, 7. <https://doi.org/10.3389/fbioe.2019.00411>
- Linardi, R. L., Dodson, M. E., Moss, K. L., King, W. J., & Orved, K. F. (2019). The Effect of Autologous Protein Solution on the Inflammatory Cascade in Stimulated Equine Chondrocytes. *Frontiers in Veterinary Science*, 6(MAR). <https://doi.org/10.3389/FVETS.2019.00064>
- Little, C. B., Flannery, C. R., Hughes, C. E., Goodship, A., & Caterson, B. (2005). Cytokine induced metalloproteinase expression and activity does not correlate with focal susceptibility of articular cartilage to degeneration. *Osteoarthritis and Cartilage*, 13(2), 162–170. <https://doi.org/10.1016/j.joca.2004.10.014>
- Liu, H., Li, D., Zhang, Y., & Li, M. (2018, April 1). Inflammation, mesenchymal stem cells and bone regeneration. *Histochemistry and Cell Biology*. Springer Verlag. <https://doi.org/10.1007/s00418-018-1643-3>
- Liu, R., Wang, Y., Li, B., Wang, H., Guan, F., Tan, Z., & Li, X. (2019). Screening differentially expressed proteins from co-cultured hematopoietic cells and bone marrow-derived stromal cells by quantitative proteomics (SILAC) method. *Clinical Proteomics*, 16(1), 1–18. <https://doi.org/10.1186/s12014-019-9249-x>
- Liu, X., Yang, Z., Sun, J., Ma, T., Hua, F., & Shen, Z. (2019). A brief review of cytotoxicity of nanoparticles on mesenchymal stem cells in regenerative medicine. *International Journal of Nanomedicine*. NLM (Medline).

- <https://doi.org/10.2147/IJN.S205574>
- Lkhagva, B., Kao, Y. H., Lee, T. I., Lee, T. W., Cheng, W. L., & Chen, Y. J. (2018). Activation of Class I histone deacetylases contributes to mitochondrial dysfunction in cardiomyocytes with altered complex activities. *Epigenetics*, *13*(4), 376–385. <https://doi.org/10.1080/15592294.2018.1460032>
- Loeser, R. F., Collins, J. A., & Diekman, B. O. (2016). Ageing and the pathogenesis of osteoarthritis. *Nature Reviews Rheumatology* *2016 12:7*, *12*(7), 412–420. <https://doi.org/10.1038/nrrheum.2016.65>
- Luan, Y., Kong, L., Howell, D. R., Ilalov, K., Fajardo, M., Bai, X. H., ... Liu, C. J. (2008). Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulin. *Osteoarthritis and Cartilage*, *16*(11), 1413–1420. <https://doi.org/10.1016/j.joca.2008.03.017>
- Lynch, K., & Pei, M. (2014). Age associated communication between cells and matrix: A potential impact on stem cell-based tissue regeneration strategies. *Organogenesis*, *10*(3), 289–298. <https://doi.org/10.4161/15476278.2014.970089>
- MacDonald, E. S., & Barrett, J. G. (2020). The Potential of Mesenchymal Stem Cells to Treat Systemic Inflammation in Horses. *Frontiers in Veterinary Science*, *6*(January), 1–14. <https://doi.org/10.3389/fvets.2019.00507>
- Madrigal, M., Rao, K., & Riordan, N. (2014). A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. *Journal of Translational Medicine*, *12*(1). <https://doi.org/10.1186/S12967-014-0260-8>
- Madzuki, I. N., Lau, S. F., Che Ahmad Tantowi, N. A., Mohd Ishak, N. I., & Mohamed, S. (2018). Labisia pumila prevented osteoarthritis cartilage degeneration by attenuating joint inflammation and collagen breakdown in postmenopausal rat model. *Inflammopharmacology*, *26*(5), 1207–1217. <https://doi.org/10.1007/s10787-018-0452-6>
- Maffioli, E., Nonnis, S., Angioni, R., Santagata, F., Cali, B., Zanotti, L., ... Tedeschi, G. (2017). Proteomic analysis of the secretome of human bone marrow-derived mesenchymal stem cells primed by pro-inflammatory cytokines. *Journal of Proteomics*, *166*, 115–126. <https://doi.org/10.1016/j.jprot.2017.07.012>
- Malda, Benders, K., Klein, T., JC, de G., Kik, M., Hutmacher, D., ... Dhert, W. (2012). Comparative study of depth-dependent characteristics of equine and human osteochondral tissue from the medial and lateral femoral condyles. *Osteoarthritis and Cartilage*, *20*(10), 1147–1151. <https://doi.org/10.1016/J.JOCA.2012.06.005>
- Maldonado, M., & Nam, J. (2013). The role of changes in extracellular matrix of cartilage in the presence of inflammation on the pathology of osteoarthritis. *BioMed Research International*, *2013*. <https://doi.org/10.1155/2013/284873>
- Malinowski, M., Pietraszek, K., Perreau, C., Boguslawski, M., Decot, V., Stoltz, J. F., ... Karamanos, N. K. (2012). Effect of Lumican on the Migration of Human Mesenchymal Stem Cells and Endothelial Progenitor Cells: Involvement of Matrix Metalloproteinase-14. *PLoS ONE*, *7*(12). <https://doi.org/10.1371/journal.pone.0050709>
- Mancuso, P., Raman, S., Glynn, A., Barry, F., & Murphy, J. M. (2019). Mesenchymal stem cell therapy for osteoarthritis: The critical role of the cell secretome. *Frontiers in Bioengineering and Biotechnology*. Frontiers Media S.A. <https://doi.org/10.3389/fbioe.2019.00009>
- Marx, C., Gardner, S., Harman, R. M., & Van de Walle, G. R. (2020). The mesenchymal stromal cell secretome impairs methicillin-resistant *Staphylococcus aureus* biofilms via cysteine protease activity in the equine model. *Stem Cells Translational Medicine*, *9*(7), 746–757. <https://doi.org/10.1002/sctm.19-0333>
- Matta, C., Fellows, C. R., Quasnichka, H., Williams, A., Jeremiasse, B., Allaway, D., & Mobasheri, A. (2020). Clusterin secretion is attenuated by the proinflammatory cytokines interleukin-1 β and tumor necrosis factor- α in models of cartilage degradation. *Journal of Orthopaedic Research*, *jor.24814*. <https://doi.org/10.1002/jor.24814>
- Maumus, M., Manferdini, C., Toupet, K., Chuchana, P., Casteilla, L., Gachet, M., ... Noël, D. (2017). Thrombospondin-1 partly mediates the cartilage protective effect of adipose-derived mesenchymal stem cells in osteoarthritis. *Frontiers in Immunology*, *8*(NOV). <https://doi.org/10.3389/fimmu.2017.01638>
- McAllister, M. J., Chemaly, M., Eakin, A. J., Gibson, D. S., & McGilligan, V. E. (2018, May 1). NLRP3 as a potentially novel biomarker for the management of osteoarthritis. *Osteoarthritis and Cartilage*. W.B. Saunders Ltd. <https://doi.org/10.1016/j.joca.2018.02.091>
- McCoy, A. M. (2015). Animal Models of Osteoarthritis: Comparisons and Key Considerations. *Veterinary Pathology*, *52*(5), 803–818. <https://doi.org/10.1177/0300985815588611>
- McIlwraith, C. W., Frisbie, D. D., & Kawcak, C. E. (2012). The horse as a model of naturally occurring osteoarthritis. *Bone & Joint Research*, *1*(11), 297–309. <https://doi.org/10.1302/2046-3758.111.2000132>
- McIlwraith, C. Wayne, Kawcak, C. E., Frisbie, D. D., Little, C. B., Clegg, P. D., Peffers, M. J., ... Kraus, V. B. (2018). Biomarkers for equine joint injury and osteoarthritis. *Journal of Orthopaedic Research*, *36*(3), 823–831. <https://doi.org/10.1002/jor.23738>
- Mehana, E. E., Khafaga, A. F., & El-blehi, S. S. (2019). The role of matrix metalloproteinases in osteoarthritis

- pathogenesis: An updated review. *Life Sciences*, 234(June), 116786. <https://doi.org/10.1016/j.lfs.2019.116786>
- Meier, F., Brunner, A. D., Koch, S., Koch, H., Lubeck, M., Krause, M., ... Mann, M. (2018). Online parallel accumulation–serial fragmentation (PASEF) with a novel trapped ion mobility mass spectrometer. *Molecular and Cellular Proteomics*, 17(12), 2534–2545. <https://doi.org/10.1074/mcp.TIR118.000900>
- Metzler, M., Pfeiffer, E., Schulz, S. I., & Dempe, J. S. (2013). Curcumin uptake and metabolism. *BioFactors*, 39(1), 14–20. <https://doi.org/10.1002/biof.1042>
- Mianehsaz, E., Mirzaei, H. R., Mahjoubin-Tehran, M., Rezaee, A., Sahebhasagh, R., Pourhanifeh, M. H., ... Hamblin, M. R. (2019, November 21). Mesenchymal stem cell-derived exosomes: A new therapeutic approach to osteoarthritis? *Stem Cell Research and Therapy*. BioMed Central Ltd. <https://doi.org/10.1186/s13287-019-1445-0>
- Mitchell, S., Vargas, J., & Hoffmann, A. (2016). Signaling via the NFκB system. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine*, 8(3), 227–241. <https://doi.org/10.1002/wsbm.1331>
- Mocchi, M., Dotti, S., Bue, M. Del, Villa, R., Bari, E., Perteghella, S., ... Grolli, S. (2020). Veterinary Regenerative Medicine for Musculoskeletal Disorders: Can Mesenchymal Stem/Stromal Cells and Their Secretome Be the New Frontier? *Cells*, 9(6). <https://doi.org/10.3390/cells9061453>
- Mödinger, Y., Rapp, A., Vikman, A., Ren, Z., Fischer, V., Bergdolt, S., ... Ignatius, A. (2019). Reduced Terminal Complement Complex Formation in Mice Manifests in Low Bone Mass and Impaired Fracture Healing. *The American Journal of Pathology*, 189(1), 147–161. <https://doi.org/10.1016/J.AJPATH.2018.09.011>
- Moll, G., Geißler, S., Catar, R., Ignatowicz, L., Hoogduijn, M. J., Strunk, D., ... Ringdén, O. (2016). Cryopreserved or fresh mesenchymal stromal cells: Only a matter of taste or key to unleash the full clinical potential of MSC therapy? In *Advances in Experimental Medicine and Biology* (Vol. 951, pp. 77–98). Springer New York LLC. https://doi.org/10.1007/978-3-319-45457-3_7
- Moo, E. K., Osman, N. A. A., & Pinguan-Murphy, B. (2011). The metabolic dynamics of cartilage explants over a long-term culture period. *Clinics*, 66(8), 1431–1436. <https://doi.org/10.1590/S1807-59322011000800021>
- Morales, T. I., & Hunziker, E. B. (2003). Localization of insulin-like growth factor binding protein-2 in chondrocytes of bovine articular cartilage. *Journal of Orthopaedic Research*, 21(2), 290–295. [https://doi.org/10.1016/S0736-0266\(02\)00154-7](https://doi.org/10.1016/S0736-0266(02)00154-7)
- Mushahary, D., Spittler, A., Kasper, C., Weber, V., & Charwat, V. (2018). Isolation, cultivation, and characterization of human mesenchymal stem cells. *Cytometry Part A*, 93(1), 19–31. <https://doi.org/10.1002/cyto.a.23242>
- Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas-Freiss, N., & Suganuma, N. (2019). Biological functions of mesenchymal stem cells and clinical implications. *Cellular and Molecular Life Sciences*, 76(17), 3323–3348. <https://doi.org/10.1007/s00018-019-03125-1>
- Nakagawa, K., Zingg, J.-M., Kim, S. H., Thomas, M. J., Dolnikowski, G. G., Azzi, A., ... Meydani, M. (2014). Differential cellular uptake and metabolism of curcuminoids in monocytes/macrophages: regulatory effects on lipid accumulation. *British Journal of Nutrition*. <https://doi.org/10.1017/S0007114514000567>
- Nelson, K. M., Dahlin, J. L., Bisson, J., Graham, J., Pauli, G. F., & Walters, M. A. (2017). The Essential Medicinal Chemistry of Curcumin. *Journal of Medicinal Chemistry*, 60(5), 1620–1637. <https://doi.org/10.1021/acs.jmedchem.6b00975>
- Nesvizhskii, A. I., Keller, A., Kolker, E., & Aebersold, R. (2003). A statistical model for identifying proteins by tandem mass spectrometry. *Analytical Chemistry*, 75(17), 4646–4658. <https://doi.org/10.1021/ac0341261>
- Neven, P., Serteyn, D., Delarge, J., Kiss, R., Mathieu, V., Cataldo, D., & Rocks, N. (2009). *WO/2009/144220*.
- Nitzsche, F., Müller, C., Lukomska, B., Jolkkonen, J., Deten, A., & Boltze, J. (2017, June 1). Concise Review: MSC Adhesion Cascade—Insights into Homing and Transendothelial Migration. *Stem Cells*. Wiley-Blackwell. <https://doi.org/10.1002/stem.2614>
- Occhetta, P., Mainardi, A., Votta, E., Vallmajo-Martin, Q., Ehrbar, M., Martin, I., ... Rasponi, M. (2019). Hyperphysiological compression of articular cartilage induces an osteoarthritic phenotype in a cartilage-on-a-chip model. *Nature Biomedical Engineering*, 3(7), 545–557. <https://doi.org/10.1038/s41551-019-0406-3>
- Ong, S., Blagoev, B., Kratchmarova, I., Kristensen, D., Steen, H., Pandey, A., & Mann, M. (2002). Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. *Molecular & Cellular Proteomics: MCP*, 1(5), 376–386. <https://doi.org/10.1074/MCP.M200025-MCP200>
- Ong, S. E., & Mann, M. (2007). A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). *Nature Protocols*, 1(6), 2650–2660. <https://doi.org/10.1038/nprot.2006.427>
- Oppenheimer, A. (1937). Turmeric (curcumin) in biliary diseases. *Lancet*, 229, 619–621.
- Ortved, K. F., & Nixon, A. J. (2016). Cell-based cartilage repair strategies in the horse. *Veterinary Journal*, 208, 1–12. <https://doi.org/10.1016/j.tvjl.2015.10.027>
- Passeri, S., Nocchi, F., Lamanna, R., Lapi, S., Miragliotta, V., Giannesi, E., ... Coli, A. (2009). Isolation and expansion of equine umbilical cord-derived matrix cells (EUCMCs). *Cell Biology International*, 33(1), 100–105. <https://doi.org/10.1016/J.CELLBI.2008.10.012>

- Pathak, N. N., Lingaraju, M. C., Balaganur, V., Kant, V., More, A. S., Kumar, D., ... Tandan, S. K. (2015). Anti-inflammatory and chondroprotective effects of atorvastatin in a cartilage explant model of osteoarthritis. *Inflammation Research*, 64(3–4), 161–169. <https://doi.org/10.1007/s00011-014-0794-5>
- Pavlou, M., & Diamandis, E. (2010). The cancer cell secretome: a good source for discovering biomarkers? *Journal of Proteomics*, 73(10), 1896–1906. <https://doi.org/10.1016/J.JPROT.2010.04.003>
- Pawlina, W. (2019). *Histology: A text and atlas*. (Lippincott, Ed.) (8th ed.).
- Pearle, A., Warren, R., & Rodeo, S. (2005). Basic science of articular cartilage and osteoarthritis. *Clinics in Sports Medicine*, 24(1), 1–12. <https://doi.org/10.1016/J.CSM.2004.08.007>
- Peffers, M. J., Cillero-Pastor, B., Eijkel, G. B., Clegg, P. D., & Heeren, R. M. (2014). Matrix assisted laser desorption ionization mass spectrometry imaging identifies markers of ageing and osteoarthritic cartilage. *Arthritis Research & Therapy*. <https://doi.org/10.1186/ar4560>
- Peffers, M. J., Collins, J., Loughlin, J., Proctor, C., & Clegg, P. D. (2016). A proteomic analysis of chondrogenic, osteogenic and tenogenic constructs from ageing mesenchymal stem cells. *Stem Cell Research & Therapy*, 7(1), 133. <https://doi.org/10.1186/s13287-016-0384-2>
- Pesta, D., & Gnaiger, E. (2012). High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. *Methods in Molecular Biology*, 810, 25–58. https://doi.org/10.1007/978-1-61779-382-0_3
- Pietrowska, M., Wlosowicz, A., Gawin, M., & Widlak, P. (2019). MS-Based Proteomic Analysis of Serum and Plasma: Problem of High Abundant Components and Lights and Shadows of Albumin Removal. In *Advances in Experimental Medicine and Biology* (Vol. 1073, pp. 57–76). Springer New York LLC. https://doi.org/10.1007/978-3-030-12298-0_3
- Piluso, S., Li, Y., Abinzano, F., Levato, R., Moreira Teixeira, L., Karperien, M., ... Malda, J. (2019). Mimicking the Articular Joint with In Vitro Models. *Trends in Biotechnology*, 37(10), 1063–1077. <https://doi.org/10.1016/j.tibtech.2019.03.003>
- Planque, C., Kulasingam, V., Smith, C., Reckamp, K., Goodglick, L., & Diamandis, E. (2009). Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. *Molecular & Cellular Proteomics: MCP*, 8(12), 2746–2758. <https://doi.org/10.1074/MCP.M900134-MCP200>
- Poole, A., Kojima, T., Yasuda, T., Mwale, F., Kobayashi, M., & Laverty, S. (2001). Composition and structure of articular cartilage: a template for tissue repair. *Clinical Orthopaedics and Related Research*, (391 Suppl). <https://doi.org/10.1097/00003086-200110001-00004>
- Priyadarsini, K. I. (2009). Photophysics, photochemistry and photobiology of curcumin: Studies from organic solutions, bio-mimetics and living cells. *Journal of Photochemistry and Photobiology C: Photochemistry Reviews*. <https://doi.org/10.1016/j.jphotochemrev.2009.05.001>
- Prosser, A., Scotchford, C., Roberts, G., Grant, D., & Sottile, V. (2019). Integrated multi-assay culture model for stem cell chondrogenic differentiation. *International Journal of Molecular Sciences*, 20(4). <https://doi.org/10.3390/ijms20040951>
- Pujol, R., Girard, C. A., Richard, H., Hassanpour, I., Binette, M. P., Beauchamp, G., ... Laverty, S. (2018). Synovial nerve fiber density decreases with naturally-occurring osteoarthritis in horses. *Osteoarthritis and Cartilage*, 26(10), 1379–1388. <https://doi.org/10.1016/j.joca.2018.06.006>
- Qiu, G., Zheng, G., Ge, M., Wang, J., Huang, R., Shu, Q., & Xu, J. (2019, November 28). Functional proteins of mesenchymal stem cell-derived extracellular vesicles. *Stem Cell Research and Therapy*. BioMed Central Ltd. <https://doi.org/10.1186/s13287-019-1484-6>
- Rademaker, G., Vincent Hennequière, • Brohée, L., Nokin, M.-J., Lovinfosse, • Pierre, Durieux, • Florence, ... Peulen, • Olivier. (2018). Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness. *Oncogene*, 37, 4398–4412. <https://doi.org/10.1038/s41388-018-0287-z>
- Ragni, E., Perucca Orfei, C., De Luca, P., Mondadori, C., Viganò, M., Colombini, A., & De Girolamo, L. (2020). Inflammatory priming enhances mesenchymal stromal cell secretome potential as a clinical product for regenerative medicine approaches through secreted factors and EV-miRNAs: The example of joint disease. *Stem Cell Research and Therapy*, 11(1). <https://doi.org/10.1186/s13287-020-01677-9>
- Redondo-Castro, E., Cunningham, C., Miller, J., Martuscelli, L., Aoulad-Ali, S., Rothwell, N. J., ... Pinteaux, E. (2017). Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro. *Stem Cell Research and Therapy*, 8(1). <https://doi.org/10.1186/s13287-017-0531-4>
- Renard, P., Ernest, I., Houbion, A., Art, M., Le Calvez, H., Raes, M., & Remacle, J. (2001). Development of a sensitive multi-well colorimetric assay for active NFκB. *Nucleic Acids Research*, 29(4). <https://doi.org/10.1093/nar/29.4.e21>
- Richardson, S. M., Kalamegam, G., Pushparaj, P. N., Matta, C., Memic, A., Khademhosseini, A., ... Mobasheri, A. (2016). Mesenchymal stem cells in regenerative medicine: Focus on articular cartilage and intervertebral disc regeneration. *Methods*, 99, 69–80. <https://doi.org/10.1016/j.ymeth.2015.09.015>

- Rocha, B., Calamia, V., Mateos, J., Fernández-Puente, P., Blanco, F. J., & Ruiz-Romero, C. (2012). Metabolic labeling of human bone marrow mesenchymal stem cells for the quantitative analysis of their chondrogenic differentiation. *Journal of Proteome Research*, *11*(11), 5350–5361. <https://doi.org/10.1021/pr300572r>
- Rozier, P., Maria, A., Goulabchand, R., Jorgensen, C., Guilpain, P., & Noël, D. (2018). Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use? *Frontiers in Immunology*, *9*(December), 2938. <https://doi.org/10.3389/fimmu.2018.02938>
- Ruiz, M., Toupet, K., Maumus, M., Rozier, P., Jorgensen, C., & Noël, D. (2020). TGFBI secreted by mesenchymal stromal cells ameliorates osteoarthritis and is detected in extracellular vesicles. *Biomaterials*, *226*, 119544. <https://doi.org/10.1016/j.biomaterials.2019.119544>
- Sacchetti, B., Funari, A., Remoli, C., Giannicola, G., Kogler, G., Liedtke, S., ... Bianco, P. (2016). No Identical “Mesenchymal Stem Cells” at Different Times and Sites: Human Committed Progenitors of Distinct Origin and Differentiation Potential Are Incorporated as Adventitial Cells in Microvessels. *Stem Cell Reports*, *6*(6), 897–913. <https://doi.org/10.1016/J.STEMCR.2016.05.011>
- Samsornraj, R. M., Raghunath, M., Nurcombe, V., Hui, J. H., van Wijnen, A. J., & Cool, S. M. (2017). Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine. *Stem Cells Translational Medicine*. <https://doi.org/10.1002/sctm.17-0129>
- Sanchez, C., Bay-Jensen, A. C., Pap, T., Dvir-Ginzberg, M., Quasnicka, H., Barrett-Jolley, R., ... Henrotin, Y. (2017, August 1). Chondrocyte secretome: a source of novel insights and exploratory biomarkers of osteoarthritis. *Osteoarthritis and Cartilage*. W.B. Saunders Ltd. <https://doi.org/10.1016/j.joca.2017.02.797>
- Sherman, A. B., Gilger, B. C., Berglund, A. K., & Schnabel, L. V. (2017). Effect of bone marrow-derived mesenchymal stem cells and stem cell supernatant on equine corneal wound healing in vitro. *Stem Cell Research & Therapy*. <https://doi.org/10.1186/s13287-017-0577-3>
- Shi, L., Liang, T., Yang, F., Zhu, F. F., Liu, J., Jiang, J. Q., ... Liang, X. L. (2021). Matrix Metalloproteinase-3 induces proteoglycan degradation in gouty arthritis model. *Gene*, *765*, 145120. <https://doi.org/10.1016/j.gene.2020.145120>
- Shin, J., Rhim, J., Kwon, Y., Choi, S. Y., Shin, S., Ha, C. W., & Lee, C. (2019). Comparative analysis of differentially secreted proteins in serum-free and serum-containing media by using BONCAT and pulsed SILAC. *Scientific Reports*, *9*(1), 1–12. <https://doi.org/10.1038/s41598-019-39650-z>
- Siengdee, P., Pradit, W., Chomdej, S., & Nganvongpanit, K. (2019). Determination of two fluoroquinolones and their combinations with hyaluronan effect in in vitro canine cartilage explants. *PeerJ*, *7*, e6553. <https://doi.org/10.7717/peerj.6553>
- Simental-Mendía, M., Lozano-Sepúlveda, S. A., Pérez-Silos, V., Fuentes-Mera, L., Martínez-Rodríguez, H. G., Acosta-Olivo, C. A., ... Vilchez-Cavazos, F. (2020). Anti-inflammatory and anti-catabolic effect of non-animal stabilized hyaluronic acid and mesenchymal stem cell-conditioned medium in an osteoarthritis coculture model. *Molecular Medicine Reports*, *21*(5), 2243–2250. <https://doi.org/10.3892/mmr.2020.11004>
- Sole, A., Spriet, M., Galuppo, L. D., Padgett, K. A., Borjesson, D. L., Wisner, E. R., ... Vidal, M. A. (2012). Scintigraphic evaluation of intra-arterial and intravenous regional limb perfusion of allogeneic bone marrow-derived mesenchymal stem cells in the normal equine distal limb using ^{99m}Tc-HMPAO. *Equine Veterinary Journal*, *44*(5), 594–599. <https://doi.org/10.1111/J.2042-3306.2011.00530.X>
- Somoza, R. A., Welter, J. F., Correa, D., & Caplan, A. I. (2014, December 1). Chondrogenic differentiation of mesenchymal stem cells: Challenges and unfulfilled expectations. *Tissue Engineering - Part B: Reviews*. Mary Ann Liebert Inc. <https://doi.org/10.1089/ten.teb.2013.0771>
- Stevens, A. L., Wheeler, C. A., Tannenbaum, S. R., & Grodzinsky, A. J. (2008). Nitric oxide enhances aggrecan degradation by aggrecanase in response to TNF- α but not IL-1 β treatment at a post-transcriptional level in bovine cartilage explants. *Osteoarthritis and Cartilage*, *16*(4), 489–497. <https://doi.org/10.1016/j.joca.2007.07.015>
- Stevens, Anna L., Wishnok, J. S., White, F. M., Grodzinsky, A. J., & Tannenbaum, S. R. (2009). Mechanical injury and cytokines cause loss of cartilage integrity and upregulate proteins associated with catabolism, immunity, inflammation, and repair. *Molecular and Cellular Proteomics*, *8*(7), 1475–1489. <https://doi.org/10.1074/mcp.M800181-MCP200>
- Stradner, M. H., Angerer, H., Ortner, T., Fuerst, F. C., Setznagl, D., Kremser, M. L., ... Graninger, W. B. (2011). The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage. *BMC Musculoskeletal Disorders*, *12*. <https://doi.org/10.1186/1471-2474-12-279>
- Strauss, E., Goodrich, L., Chen, C.-T., Hidaka, C., & Nixon, A. (2005). Biochemical and biomechanical properties of lesion and adjacent articular cartilage after chondral defect repair in an equine model. *The American Journal of Sports Medicine*, *33*(11), 1647–1653. <https://doi.org/10.1177/0363546505275487>
- Strehl, R., Tallheden, T., Sjögren-Jansson, E., Minuth, W. W., & Lindahl, A. (2005). Long-term maintenance of human articular cartilage in culture for biomaterial testing. *Biomaterials*, *26*(22), 4540–4549. <https://doi.org/10.1016/j.biomaterials.2004.11.037>
- Sun, D. Z., Abelson, B., Babbar, P., & Damaser, M. S. (2019, June 1). Harnessing the mesenchymal stem cell

- secretome for regenerative urology. *Nature Reviews Urology*. Nature Publishing Group. <https://doi.org/10.1038/s41585-019-0169-3>
- Swärd, P., Wang, Y., Hansson, M., Lohmander, L., Grodzinsky, A., & Struglics, A. (2017). Coculture of bovine cartilage with synovium and fibrous joint capsule increases aggrecanase and matrix metalloproteinase activity. *Arthritis Research & Therapy*, *19*(1). <https://doi.org/10.1186/S13075-017-1318-9>
- Textor, J., Willits, N., & Tablin, F. (2013). Synovial fluid growth factor and cytokine concentrations after intra-articular injection of a platelet-rich product in horses. *Veterinary Journal (London, England : 1997)*, *198*(1), 217–223. <https://doi.org/10.1016/J.TVJL.2013.07.020>
- Thysen, S., Luyten, F. P., & Lories, R. J. U. (2015). Targets, models and challenges in osteoarthritis research. *DMM Disease Models and Mechanisms*, *8*(1), 17–30. <https://doi.org/10.1242/dmm.016881>
- Tnibar, A., Schougaard, H., Camitz, L., Rasmussen, J., Koene, M., Jahn, W., & Markussen, B. (2015). An international multi-centre prospective study on the efficacy of an intraarticular polyacrylamide hydrogel in horses with osteoarthritis: a 24 months follow-up. *Acta Veterinaria Scandinavica*, *57*(1). <https://doi.org/10.1186/S13028-015-0110-6>
- Tortorella, M. D., Malfait, A. M., Deccico, C., & Arner, E. (2001). The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. *Osteoarthritis and Cartilage*, *9*(6), 539–552. <https://doi.org/10.1053/joca.2001.0427>
- Trachana, V., Mourmoura, E., Papathanasiou, I., & Tsezou, A. (2019). Understanding the role of chondrocytes in osteoarthritis: utilizing proteomics. *Expert Review of Proteomics*, *16*(3), 201–213. <https://doi.org/10.1080/14789450.2019.1571918>
- Usas, A., & Huard, J. (2007). Muscle-derived stem cells for tissue engineering and regenerative therapy. *Biomaterials*, *28*(36), 5401–5406. <https://doi.org/10.1016/j.biomaterials.2007.09.008>
- Van Den Bosch, M. H. J. (2021). Osteoarthritis year in review 2020: biology. *Osteoarthritis and Cartilage*, *29*, 143–150. <https://doi.org/10.1016/j.joca.2020.10.006>
- Van Offel, J. F., Dombrecht, E. J., Bridts, C. H., Schuerwegh, A. J., Ebo, D. G., Stevens, W. J., & De Clerck, L. S. (2005). Influence of bisphosphonates on the production of pro-inflammatory cytokines by activated human articular chondrocytes. *Cytokine*, *31*(4), 298–304. <https://doi.org/10.1016/j.cyto.2005.05.009>
- van Weeren, P. R., & Back, W. (2016). Musculoskeletal Disease in Aged Horses and Its Management. *Veterinary Clinics of North America - Equine Practice*, *32*(2), 229–247. <https://doi.org/10.1016/j.cveq.2016.04.003>
- Vidal, M. A., Kilroy, G. E., Lopez, M. J., Johnson, J. R., Moore, R. M., & Gimble, J. M. (2007). Characterization of equine adipose tissue-derived stromal cells: Adipogenic and osteogenic capacity and comparison with bone marrow-derived mesenchymal stromal cells. *Veterinary Surgery*, *36*(7), 613–622. <https://doi.org/10.1111/j.1532-950X.2007.00313.x>
- Vizoso, F. J., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017). Mesenchymal stem cell secretome: Toward cell-free therapeutic strategies in regenerative medicine. *International Journal of Molecular Sciences*, *18*(9). <https://doi.org/10.3390/ijms18091852>
- Voga, M., Adamic, N., Vengust, M., & Majdic, G. (2020). Stem Cells in Veterinary Medicine—Current State and Treatment Options. *Frontiers in Veterinary Science*, *7*(May), 1–20. <https://doi.org/10.3389/fvets.2020.00278>
- Votion, D. M., Gnaiger, E., Lemieux, H., Mouithys-Mickalad, A., & Serteyn, D. (2012). Physical fitness and mitochondrial respiratory capacity in horse skeletal muscle. *PLoS ONE*, *7*(4). <https://doi.org/10.1371/journal.pone.0034890>
- Wang, X., Zhang, Y., Yang, Y., Zhang, W., Luo, L., Han, F., ... Hu, D. (2019). Curcumin pretreatment protects against hypoxia/reoxygenation injury via improvement of mitochondrial function, destabilization of HIF-1 α and activation of Epac1-Akt pathway in rat bone marrow mesenchymal stem cells. *Biomedicine and Pharmacotherapy*, *109*(127), 1268–1275. <https://doi.org/10.1016/j.biopha.2018.11.005>
- Wang, Y., Tang, Q., Duan, P., & Yang, L. (2018). Curcumin as a therapeutic agent for blocking NF- κ B activation in ulcerative colitis. *Immunopharmacology and Immunotoxicology*. <https://doi.org/10.1080/08923973.2018.1469145>
- Weinmann, D., Mueller, M., Walzer, S. M., Hobusch, G. M., Lass, R., Gahleitner, C., ... Toegel, S. (2018). Brazilin blocks catabolic processes in human osteoarthritic chondrocytes via inhibition of NFKB1/p50. *Journal of Orthopaedic Research*, *36*(9), 2431–2438. <https://doi.org/10.1002/jor.24013>
- Weiss, A. R. R., & Dahlke, M. H. (2019). Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of action of living, apoptotic, and dead MSCs. *Frontiers in Immunology*. Frontiers Media S.A. <https://doi.org/10.3389/fimmu.2019.01191>
- Weiss, D. J., English, K., Krasnodembskaya, A., Isaza-Correa, J. M., Hawthorne, I. J., & Mahon, B. P. (2019, June 4). The necrobiology of mesenchymal stromal cells affects therapeutic efficacy. *Frontiers in Immunology*. Frontiers Media S.A. <https://doi.org/10.3389/fimmu.2019.01228>
- Wilkinson, D. J., Arques, M. del C., Huesa, C., & Rowan, A. D. (2019, January 1). Serine proteinases in the turnover of the cartilage extracellular matrix in the joint: implications for therapeutics. *British Journal of*

- Pharmacology*. John Wiley and Sons Inc. <https://doi.org/10.1111/bph.14173>
- Wojdasiewicz, P., Poniatowski, Ł. A., & Szukiewicz, D. (2014). The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. *Mediators of Inflammation*. Hindawi Publishing Corporation. <https://doi.org/10.1155/2014/561459>
- Yamada, Y., Nakamura-Yamada, S., Umemura-Kubota, E., & Baba, S. (2019). Diagnostic cytokines and comparative analysis secreted from exfoliated deciduous teeth, dental pulp, and bone marrow derived mesenchymal stem cells for functional cell-based therapy. *International Journal of Molecular Sciences*, 20(23). <https://doi.org/10.3390/ijms20235900>
- Yamamoto, K., Wilkinson, D., & Bou-Gharios, G. (2020). Targeting Dysregulation of Metalloproteinase Activity in Osteoarthritis. *Calcified Tissue International*. Springer. <https://doi.org/10.1007/s00223-020-00739-7>
- Yan, D., He, B., Guo, J., Li, S., & Wang, J. (2019). Involvement of TLR4 in the protective effect of intra-articular administration of curcumin on rat experimental osteoarthritis. *Acta Cirurgica Brasileira*, 34(6). <https://doi.org/10.1590/s0102-865020190060000004>
- Yan, G., You, B., Chen, S.-P., Liao, J. K., & Sun, J. (2008). TNF-alpha Downregulates Endothelial Nitric Oxide Synthase mRNA Stability via Translation Elongation Factor 1-alpha 1. *Circ Res*, 103(6), 591–597. <https://doi.org/10.1161/CIRCRESAHA.108.173963>
- Yu, B., Yang, Y., Liu, H., Gong, M., Millard, R. W., Wang, Y. G., ... Xu, M. (2016). Clusterin/Akt up-regulation is critical for GATA-4 mediated cytoprotection of mesenchymal stem cells against ischemia injury. *PLoS ONE*, 11(3). <https://doi.org/10.1371/journal.pone.0151542>
- Zanotto, G., & Frisbie, D. (2021). Current joint therapy usage in equine practice: changes in the last 10 years. *Equine Veterinary Journal*. <https://doi.org/10.1111/EVJ.13489>
- Zayed, M., Adair, S., Ursini, T., Schumacher, J., Misk, N., & Dhar, M. (2018). Concepts and challenges in the use of mesenchymal stem cells as a treatment for cartilage damage in the horse. *Research in Veterinary Science*. <https://doi.org/10.1016/j.rvsc.2018.03.011>
- Zeira, O., Scaccia, S., Pettinari, L., Ghezzi, E., Asiag, N., Martinelli, L., ... Aralla, M. (2018). Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue in Dogs with Spontaneous Osteoarthritis: Safety, Feasibility, and Clinical Outcomes. *Stem Cells Translational Medicine*, 7(11), 819–828. <https://doi.org/10.1002/SCTM.18-0020>
- Zeng, L., Yang, K., Hao, W., Yu, G., & Chen, H. (2021). The efficacy and safety of Curcuma longa Extract and curcumin supplements on osteoarthritis: a systematic review and meta-analysis. *Bioscience Reports*. <https://doi.org/10.1042/BSR20210817>
- Zhang, R., Ma, J., Han, J., Zhang, W., & Ma, J. (2019). Mesenchymal stem cell related therapies for cartilage lesions and osteoarthritis. *American Journal of Translational Research*, 11(10), 6275–6289. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/31737182>
- Zhang, S., Chuah, S. J., Lai, R. C., Hui, J. H. P., Lim, S. K., & Toh, W. S. (2018). MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. *Biomaterials*, 156, 16–27. <https://doi.org/10.1016/j.biomaterials.2017.11.028>
- Zhao, J., Sun, X. B., Ye, F., & Tian, W. X. (2011). Suppression of fatty acid synthase, differentiation and lipid accumulation in adipocytes by curcumin. *Molecular and Cellular Biochemistry*, 351(1–2), 19–28. <https://doi.org/10.1007/s11010-010-0707-z>
- Zhao, X., Zhao, Y., Sun, X., Xing, Y., Wang, X., & Yang, Q. (2020, October 29). Immunomodulation of MSCs and MSC-Derived Extracellular Vesicles in Osteoarthritis. *Frontiers in Bioengineering and Biotechnology*. Frontiers Media S.A. <https://doi.org/10.3389/fbioe.2020.575057>
- Zucca, E., Corsini, E., Galbiati, V., Lange-Consiglio, A., & Ferrucci, F. (2016). Evaluation of amniotic mesenchymal cell derivatives on cytokine production in equine alveolar macrophages: An in vitro approach to lung inflammation. *Stem Cell Research and Therapy*, 7(1). <https://doi.org/10.1186/s13287-016-0398-9>